

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effectiveness and cost-effectiveness of a multifaceted eHealth strategy to improve back pain beliefs of patients with non-specific low back pain: a cluster randomised trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030879
Article Type:	Original research
Date Submitted by the Author:	04-Apr-2019
Complete List of Authors:	Suman, Arnela; Amsterdam UMC - Locatie VUMC Schaafsma, F; Amsterdam UMC - Locatie VUMC van Dongen, Johanna M.; Vrije Universiteit Amsterdam Elders, Petra; Amsterdam UMC - Locatie VUMC Buchbinder, Rachelle; Monash University Tulder, Maurits; Vrije Universiteit Amsterdam Anema, Johannes; Amsterdam UMC - Locatie VUMC
Keywords:	LOW BACK PAIN, COSTS AND COST ANALYSIS, RANDOMIZED CONTROLLED TRIAL, E-HEALTH, OCCUPATIONAL HEALTH, HEALTH CARE ECONOMICS

SCHOLARONE™
Manuscripts

1
2
3 1 **Effectiveness and cost-effectiveness of a multifaceted eHealth strategy to improve back**
4
5 2 **pain beliefs of patients with non-specific low back pain: a cluster randomised trial**
6
7
8
9 3

10
11 4 Arnela Suman, Frederieke G. Schaafsma, Johanna M van Dongen, Petra JM Elders, Rachelle
12
13 5 Buchbinder, Maurits W van Tulder, Johannes R Anema
14
15
16
17 6

18
19
20 7 Corresponding author: Arnela Suman, Amsterdam UMC, VU University Amsterdam,
21
22 8 department of Public and Occupational Health, Amsterdam Public Health research institute,
23
24 9 De Boelelaan 1117, 1081HV Amsterdam, The Netherlands; a.suman@vumc.nl; 0031-20-
25
26 10 4445685
27
28
29

30 11
31
32
33 12 Frederieke G Schaafsma, Amsterdam UMC, VU University Amsterdam, department of Public
34
35 13 and Occupational Health, Amsterdam Public Health research institute, Amsterdam, The
36
37 14 Netherlands
38
39
40
41 15

42
43
44 16 Johanna M van Dongen, VU University Amsterdam, department of Health Sciences,
45
46 17 Amsterdam Public Health research institute, Amsterdam, The Netherlands
47
48
49
50 18

51
52
53 19 Petra JM Elders, Amsterdam UMC, VU University Amsterdam, department of General
54
55 20 Practice and Elderly Care, Amsterdam Public Health research institute, Amsterdam, The
56
57 21 Netherlands
58
59
60

1
2
3 22 Rachelle Buchbinder, Monash Department of Clinical Epidemiology, Cabrini Institute and
4
5 23 Department of Epidemiology and Preventive Medicine, School of Public Health & Preventive
6
7 24 Medicine, Monash University, Victoria, Australia
8
9

10
11 25
12

13
14 26 Maurits W van Tulder, VU University Amsterdam, department of Health Sciences
15
16 27 Amsterdam Public Health research institute, Amsterdam, The Netherlands
17
18

19 28
20

21
22 29 Johannes R Anema, Amsterdam UMC, VU University Amsterdam, department of Public and
23
24 30 Occupational Health, Amsterdam Public Health research institute, Amsterdam, The
25
26 31 Netherlands
27
28

29
30 32
31

32 33 Word count: 3743
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 34 **ABSTRACT**
4
5

6 35 **Background** Low back pain is the world's leading cause of disability and has a high burden
7
8 36 on individuals and societies. Many guidelines recommend self-management for patients with
9
10 37 low back pain. The current study aims to assess whether a multifaceted eHealth strategy is
11
12 38 effective and cost-effective compared to usual care in improving patients' back pain beliefs
13
14 39 and quality of life, and in decreasing their disability and absenteeism.
15
16

17
18 40 **Methods** This study was a stepped wedge cluster randomised controlled trial with a parallel
19
20 41 economic evaluation performed from a societal perspective. Four clusters of general and
21
22 42 physiotherapy practices and occupational physicians were randomised and recruited patients
23
24 43 with low back pain for this study. 779 patients participated in this study, of which 331 were
25
26 44 randomised to the intervention group (multifaceted eHealth strategy), and 448 were
27
28 45 randomised to the control group (usual care). All patients were followed up at 3, 6, and 12
29
30 46 months.
31
32

33
34
35 47 **Results** There were no between-group differences in back pain beliefs or other health
36
37 48 outcomes at any time point. While the intervention group had lower costs due to absenteeism,
38
39 49 presenteeism, and unpaid productivity losses, none of the costs were significantly different to
40
41 50 the control group. At baseline, 37% of participants did not have back pain anymore.
42
43
44

45 51 **Conclusion** The study results show that the multifaceted eHealth strategy was not effective or
46
47 52 cost-effective in improving patients' back pain beliefs and quality of life, and in decreasing
48
49 53 their disability and absenteeism.
50
51
52

53 54 **Trial registration** Netherlands Trial Register (NTR), number: NTR4329.
54
55
56

56 55
57
58
59
60

57 **Strengths and limitations of this study**

- 58 • Robust study design: stepped-wedge cluster randomised controlled trial
- 59 • Comprehensive, multifaceted e-Health strategy for low back pain
- 60 • Effectiveness and cost-effectiveness evaluated
- 61 • High rate of loss to follow-up in intervention group (40%) compared to control group
62 (23%)

64 **Funding statement**

65 This study was funded by the Netherlands Organisation for Health Research and
66 Development (ZonMw), grant number 80-83700-98-133053.

68 **Competing Interests**

69 All authors have completed the ICMJE uniform disclosure form at
70 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
71 submitted work (other than funding agency); no financial relationships with any organisations
72 that might have an interest in the submitted work in the previous three years; no other
73 relationships or activities that could appear to have influenced the submitted work.

75 **Authors Statement**

76 AS collected, prepared, and analysed data and prepared the manuscript. JMvD assisted in
77 cost-effectiveness analyses, interpreted data, and revised the manuscript. FGS, PJME, RB,

1
2
3 78 MWvT, and JRA were all involved in design of the study, interpretation of data, and revising
4
5 79 the manuscript for intellectual content.
6
7
8
9 80

10
11 81 **Data sharing**
12
13

14
15 82 Relevant data are available upon reasonable request.
16
17
18 83

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

84 BACKGROUND

85 Low back pain (LBP) is a major medical problem throughout the world. The global 1-month
86 point prevalence is estimated to be 23.2%.^[1] LBP is the leading cause of musculoskeletal and
87 work disability, and years lived with disability (YLDs) worldwide.^[2-3] Recent estimates from
88 the Global Burden of Disease Study indicate that LBP accounts for 57 million YLDs, and that
89 over 250 million people develop LBP annually.^[2] The economic burden of LBP is high.
90 Estimates of the annual economic burden of LBP vary from between AU\$9.17 billion in
91 Australia, £12.3 billion in the UK, and US\$91 billion in the United States.^[4-6] In the
92 Netherlands, recent estimates report the costs of LBP to be around €1.3 billion, a quarter of all
93 healthcare costs due to musculoskeletal disorders.^[7] However, indirect costs due to
94 absenteeism, and productivity losses due to disability are not included in this estimate.
95 Previous research has shown that indirect costs make up 88% of all societal costs due to
96 LBP.^[8] Since LBP leads to a high proportion of work absence, the costs of LBP in the
97 Netherlands are much higher than suggested.^[7] Besides the burden on society, LBP has a high
98 burden on the lives of individuals. Over the past decades, several studies have shown that
99 people with negative back pain beliefs have more pain, disability, negative work-related
100 outcomes (i.e. productivity loss and sickness absence), and higher health care utilization.^[9-12]
101 Many guidelines for LBP recommend self-management for patients, which is a reflection of a
102 newly proposed definition of health, i.e. “health as the ability to adapt and self-manage.”^[13-14]
103 A systematic review on the effectiveness of education programmes designed to improve self-
104 management suggested that these programmes are effective in improving pain intensity and
105 disability, but did not measure actual self-management.^[15]
106 Underlined by the high economic, societal, and individual burden of LBP, no highly effective
107 treatment for LBP has yet been found. However, eHealth, which is the provision of
108 (personalised) health care at a distance (e.g. through internet and thus digital), has shown

1
2
3 109 promise with regards to its' effectiveness and cost-effectiveness in improving outcomes such
4
5 110 as patient health, patient satisfaction, self-management and healthcare costs in patients with
6
7 111 physical diseases.^[16-17] Therefore, the current study aimed to assess whether a multifaceted
8
9 112 eHealth strategy to improve belief, knowledge, and self-management of LBP is effective and
10
11 113 cost-effective compared to usual care in improving patients' back pain beliefs and quality of
12
13
14 114 life, and in decreasing their disability and absenteeism.
15
16
17
18 115

For peer review only

116 **METHODS**

117 **Study design**

118 This study was part of a cluster-randomised controlled trial that was registered in 2013 with
119 the Netherlands Trial Register (NTR) under number NTR4329.^[18] The Medical Ethics
120 Committee of the VU University medical centre assessed this study's design and procedures,
121 and in accordance with the local regulatory guidelines and standards for human subjects
122 protection in the Netherlands (Medical Research Involving Human Subjects Act [WMO],
123 2005), this study proved to be exempt from further medical ethical review. A detailed
124 description of the design of this study has been published elsewhere.^[18]

125 **Participants**

126 Twenty-five general practices, 19 physiotherapy practices, and 29 occupational physicians in
127 the Amsterdam area participated in this study and recruited patients for this trial. Patients
128 were aged 18-75 years and were diagnosed with nonspecific LBP by their general practitioner
129 (GP) or physiotherapist (PT), whom they had visited due to back complaints no longer than 3
130 months prior to inclusion in the study. Nonspecific LBP was defined as LBP with or without
131 motor and/or sensory deficits in one or both legs, including sciatica and radiculopathy, that is
132 not caused by underlying specific pathology (red flags), i.e. a tumour, (osteoporotic) vertebral
133 fracture, ankylosing spondylitis, and cauda equina syndrome. Exclusion criteria were: serious
134 comorbidities including Alzheimer's disease, multiple sclerosis, Parkinson's disease,
135 amyotrophic lateral sclerosis, cerebrovascular accident in the last year, confirmed pregnancy
136 in the last year, malignancy in the last five years, and severe psychiatric disorders, i.e.
137 schizophrenia and bipolar disorder.

138 **Randomisation**

1
2
3 139 This study was a stepped-wedge cluster randomised controlled trial. The participating general
4
5 140 practices, physiotherapy practices, and occupational physicians were assigned to one of four
6
7 141 clusters based on their geographic proximity to each other. The clusters sequentially received
8
9 142 a multifaceted continuing medical education training (see Figure 1). This clustering allowed
10
11 143 for minimisation of contamination between the participants. Patients were allocated according
12
13 144 to the group their general practitioner, physiotherapist or occupational physician were
14
15 145 assigned, i.e., patients registered within a practice that was in the control group at time of
16
17 146 enrolment were allocated to the control group for patients. Randomisation was performed by
18
19 147 means of computer-generated allocation. An independent research assistant performed the
20
21 148 concealed allocation, enrolling of participants, and assignment of participants to groups.
22
23
24
25
26

27 149 **Intervention and control**

28
29
30 150 The intervention was provided to patients on an individual level. Patients in the cluster whose
31
32 151 GP or PT was randomised into the intervention group received access to a multifaceted
33
34 152 eHealth strategy that aimed to reduce patients' negative back pain beliefs and improve their
35
36 153 knowledge and self-management of LBP. The campaign included an informative website,
37
38 154 digital monthly newsletters, and social media platforms. The website provided comprehensive
39
40 155 information about LBP, such as practical advice (e.g. on self-management), working and
41
42 156 returning to work with LBP, exercise tips, and short video messages. In these videos, actors
43
44 157 and healthcare professionals shared their experiences with LBP and provided tips on self-
45
46 158 management, coping, and working with LBP. The videos were inspired by the effective
47
48 159 Australian mass media campaign 'Back Pain: Don't Take It Lying Down'.^[19] Social media
49
50 160 platforms included a forum on the website, and a Facebook page where patients could contact
51
52 161 researchers, healthcare providers, and other patients. All parts of the intervention were also
53
54 162 available in a mobile version that was adaptive to any electronic device. The patient
55
56 163 intervention was supported by continuing medical education for GPs, PTs, and occupational
57
58
59
60

1
2
3 164 physicians (OPs). More detailed descriptions of the patient and professional based
4
5 165 interventions are published elsewhere.^[20-21] Patients in the control group received a digital
6
7 166 patient information letter and had no access to the intervention website, materials or social
8
9 167 media platforms. Results of the professional based intervention will be published elsewhere.
10
11
12

13 168 **Sample size and outcomes**

14
15
16 169 The primary outcome measure was back pain beliefs, assessed using the Back Beliefs
17
18 170 Questionnaire (BBQ). The BBQ is designed to measure the inevitable consequences of LBP
19
20 171 (e.g. there is no real treatment for back trouble, back trouble must be rested). It is a validated
21
22 172 questionnaire consisting of 14 items, and rates back pain beliefs on a scale of 9 to 45, with
23
24 173 higher scores indicating more positive (better) back pain beliefs (e.g. exercising through LBP
25
26 174 is good).^[22-23]
27
28
29

30
31 175 The sample size calculation was based on a hypothesized 10% improvement in back pain
32
33 176 beliefs as measured by the BBQ, based on an observed mean improvement of 9.6% between
34
35 177 three successive surveys in the Australian campaign.^[19] An intra-class correlation coefficient
36
37 178 (ICC) of 0.05 was applied to adjust for the cluster randomisation design. Assuming a 10 %
38
39 179 improvement from a mean score of 26.5 (95% Confidence Interval (CI) 26.1-26.8, SD 6) on
40
41 180 the BBQ, and applying an ICC of 0.05, the necessary sample size was estimated to be 500
42
43 181 patients. This calculation takes into account a dropout-rate of 20%, power (1-beta) of 0.90 and
44
45 182 an alpha of 0.05.
46
47
48
49

50 183 The secondary outcomes included disability, measured with the Roland Disability
51
52 184 Questionnaire (RDQ-24), which has been shown to be a valid and reliable instrument for
53
54 185 patients with LBP.^[24] The RDQ-24 consists of 24 items, rating disability on a scale of 0 to 24,
55
56 186 with higher scores indicating more disability. The EQ-5D-3L was used to measure quality of
57
58 187 life.^[25] Health care use, absenteeism, presenteeism and unpaid productivity losses were
59
60

1
2
3 188 measured with the generic PROductivity and DIsease Questionnaire (PRODISQ) and the
4
5 189 Healthcare Utilization and Productivity Losses Questionnaire (TIC-P).^[26-27] All outcomes
6
7
8 190 were measured at baseline and after 3, 6, and 12 months follow-up.
9

10
11 191 For the economic evaluation, the scores on the EQ-5D-3L were converted into utility scores
12
13 192 using the Dutch tariff.^[28] These utility scores range from 0 (death) to 1 (maximum health.
14
15 193 Quality adjusted life years (QALYs) were calculated using linear interpolation between
16
17 194 measurement points. Societal costs included intervention costs, costs for the use of healthcare,
18
19 195 and costs for informal care (e.g. care by family and other volunteers), work absenteeism, and
20
21 196 paid and unpaid productivity losses. The intervention costs comprised all costs for the
22
23 197 development and implementation of the intervention, including costs for materials and
24
25 198 personnel (Appendix 1). There were no costs for the intervention for the control group.
26
27 199 Healthcare utilization included primary healthcare (e.g. GP, PT), secondary healthcare (e.g.
28
29 200 diagnostic imaging, medical specialist), alternative healthcare (e.g. acupuncture or massage),
30
31 201 and medication (both prescribed and over-the-counter).
32
33
34
35
36

37 202 To value healthcare utilization, prices from the Dutch Manual for Costing (DMC) were
38
39 203 used.^[29] Where standard costs were unavailable, we used prices provided by professional
40
41 204 organizations. Medication use was valued using the prices of the Royal Dutch Society of
42
43 205 Pharmacy.^[30] Informal care was valued using a recommended Dutch shadow price according
44
45 206 to the DMC.^[29] Absenteeism was calculated and valued using patient data collected with the
46
47 207 PRODISQ and TIC-P. In accordance with the DMC, patients' daily absenteeism cost was
48
49 208 calculated by dividing their self-reported gross annual salary by their total number of
50
51 209 workable days per year. Using the Friction Cost Approach (FCA, friction period 23 weeks),
52
53 210 absenteeism costs were estimated by multiplying the total number of sick leave days during
54
55 211 follow-up by their associated costs. Presenteeism was calculated using patient data collected
56
57 212 with the TIC-P questionnaire, where patients indicated how many days they went to work
58
59
60

1
2
3 213 while having LBP. To obtain workday equivalents lost to presenteeism, this number of days
4
5 214 was multiplied by a self-reported inefficiency score ranging between 0 (could not perform any
6
7 215 tasks) and 1 (could perform all tasks as efficient as without LBP). Presenteeism costs were
8
9 216 subsequently calculated by multiplying the total number of presenteeism days by their
10
11 217 associated costs.

15 218 **Statistical analyses**

17
18 219 Analyses were performed according to the intention-to-treat principle. Descriptive statistics
19
20 220 were used to compare baseline characteristics between intervention and control group
21
22 221 participants as well as between participants with complete and incomplete data. Missing
23
24 222 values for costs and effects were imputed using multiple imputation, and imputations were
25
26 223 performed separately for the intervention and control group.^[31-32] Effectiveness analyses were
27
28 224 performed using maximum likelihood estimation longitudinal mixed-effects models with
29
30 225 multilevel structure and ‘missing at random’ assumptions.^[33] The mixed-effects models
31
32 226 adjusted for the effect of clustering. Analyses of effect and cost data were performed in Stata
33
34 227 14, and the statistical significance level was set at $p < 0.05$. Regression coefficients or odds
35
36 228 ratios (ORs) were calculated with 95%-confidence intervals (CIs).

37
38 229 Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed from a
39
40 230 societal perspective. Imputation models included intervention costs, age, gender, educational
41
42 231 level, nationality, being employed, performing physically demanding work, physical activity
43
44 232 (minutes per week), and available cost and effect measure values. Using predictive mean
45
46 233 matching, 10 complete data sets were created (loss-of-efficiency 5%).^[34] Pooled estimates
47
48 234 were calculated using Rubin’s rules.^[35] Cost and effect difference estimates between
49
50 235 intervention and control group were analysed using seemingly unrelated regression (SUR),
51
52 236 while simultaneously adjusting for the possible correlation between costs and effects.^[36]
53
54
55
56
57
58
59
60

1
2
3 237 Incremental cost-effectiveness ratios (ICERs) were calculated by dividing the adjusted mean
4
5 238 cost differences by those in effects. Uncertainty surrounding the cost differences and ICERs
6
7
8 239 was estimated using Bias Corrected and Accelerated bootstrapping (BCA) with 5000
9
10 240 replications, and presented by 95%-CIs and plotted on cost-effectiveness planes.^[37] Cost-
11
12 241 effectiveness acceptability curves (CEACs) presented the probability of the intervention being
13
14 242 cost-effectiveness at different values of willingness to pay.^[38]

17 243 **Patient involvement**

18
19
20
21 244 The Dutch patient association for spinal disorders (“NVV De Wervelkolom”) was involved in
22
23 245 the design of this study and provided advice about the content of the intervention.
24
25

26 246
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

247 **RESULTS**

248 **Participants**

249 In total, 5181 eligible patients were invited to participate in this study. Of these patients, 779
250 (response rate of 15%) agreed to participate and were randomised to the intervention (n=331)
251 and control (n=448) groups (Figure 2). Follow-up responses in the intervention group were
252 69.8% at 3 months follow-up, 70.1% at 6 months follow-up, and 60.4% at 12 months follow-
253 up. The follow-up responses in the control group were higher than in the intervention group at
254 3 months follow-up (77%) and 12 months follow-up (77.5%). At 6 months follow up the
255 responses in the control group were similar to those in the intervention group (69.6%).

256 At baseline, characteristics of patients in the intervention group were similar to those in the
257 control group. Table 1 shows that a high percentage of participants were female, 60%
258 (intervention group) and 57% (control group) had a high educational level, and over half of
259 the participants were employed. They performed about 3 hours of physical activity per week.
260 Table 1 also shows the baseline scores on the BBQ, RDQ-24, absenteeism, and quality of life
261 for both groups. At baseline, there was a lower absenteeism rate in the intervention group
262 compared to the control group.

263 *Table 1. Baseline characteristics of patients*

	Intervention (n=331)	Control (n=448)
Mean age (SD)	55.7 (13.9) (n=320)	56.6 (14.6) (n=439)
Female gender (%)	188 (59) (n=320)	252 (57) (n=439)
Back pain at baseline (%)	201 (63) (n=320)	275 (63) (n=439)
Nationality (%)	(n=320)	(n=439)
- Dutch	298 (93)	409 (93)
- Western countries immigrant	16 (5)	23 (5)
- Non-western countries immigrant	6 (2)	7 (2)
Educational level (%)	(n=320)	(n=439)
- None (never attended school):	9 (3)	12 (3)
- Lower	25 (8)	42 (10)
- Vocational	92 (29)	134 (30)
- Higher	194 (60)	251 (57)
Activity minutes/week (SD)	161 (109) (n=196)	166 (104) (n=254)
Employed (paid work) (%)	183 (57) (n=320)	232 (53) (n=439)
Physically demanding work (%)	88 (28) (n=320)	121 (28) (n=439)
Back pain beliefs <i>(measured by BBQ, range 9-45; higher score means more positive back pain beliefs)</i>	24.7 (6.0) (n=295)	24.8 (6.2) (n=394)
Disability <i>(measured by RDQ-24, range 0-24; higher score means more disability)</i>	5.1 (4.7) (n=317)	5.9 (5.3) (n=434)
Absenteeism <i>(self-reported number of days over past three months)</i>	2.2 (7.0) (n=187)	4.0 (13.2) (n=246)
Quality of life <i>(utility score measured by EQ-5D; range 0 to 1; higher score means better quality of life)</i>	0.79 (0.22) (n=331)	0.75 (0.25) (n=448)

264

265 **Intention-to-treat effectiveness analysis**

266 Table 2 shows the mean scores on the BBQ, RDQ-24, absenteeism, and quality of life of the
 267 intervention group compared to the control group. Table 3 shows the results of the intention-
 268 to-treat analysis. There were no significant differences in back pain beliefs, disability and
 269 absenteeism between groups at any time point. The interaction term with gender was
 270 significant for disability, showing that the effect for males was larger than that for females.

271

272 *Table 2. Mean scores (SD) on BBQ, RDQ-24, EQ-5D and absenteeism*

	Mean (SD) back pain beliefs <i>(measured by BBQ, range 9-45; higher score means more positive back pain beliefs)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	24.4 (5.8)	24.0 (5.9)	24.1 (5.8)
Control group	24.9 (6.2)	24.6 (6.0)	24.1 (6.3)
	Mean (SD) disability <i>(measured by RDQ-24, range 0-24; higher score means more disability)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	4.4 (4.7)	3.9 (4.3)	3.9 (4.3)
Control group	5.2 (5.1)	4.8 (4.8)	4.5 (4.7)
	Mean (SD) absenteeism <i>(self-reported number of days over past three months)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up

Intervention group	1.2 (6.5)	0.9 (4.8)	0.7 (2.7)
Control group	2.6 (9.8)	0.7 (4.1)	0.7 (4.4)
	Mean (SD) quality of life <i>(utility score measured by EQ-5D; range 0 to 1; higher score means better quality of life)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	0.86 (0.21)	0.90 (0.16)	0.91 (0.15)
Control group	0.82 (0.24)	0.86 (0.21)	0.87 (0.19)

273

274 *Table 3. Adjusted effects of the intervention based on intention-to-treat analyses*

Outcome		Difference between intervention and control	95%-CI
Back beliefs¹		-0.13	-0.90;0.65
Disability	M	-1.13	0.93;1.37
	F	-0.79	0.68;0.93
Absenteeism^{2;3}		-0.94	0.69;1.29

275 1: Adjusted for educational level, physical activity, having back pain, being employed, comorbidity; 2: Adjusted
 276 for age, physical activity, having back pain; 3: Only for participants who were employed at baseline
 277 (intervention group n=183; control group n=232)

278

279 **Cost-effectiveness analysis**

280 Intervention costs per patient were € 70. Direct costs for primary care and medication were
 281 lower in the intervention than in the control group, while direct costs for secondary and
 282 alternative care were higher in the intervention than in the control group. Indirect costs due to

absenteeism, presenteeism, and unpaid productivity loss were lower in the intervention than in the control group. The crude total cost differences were not significant (Table 4).

Table 4. Crude costs per cost category in euros (€)

Cost category	Mean costs (SEM) in €		Δ Costs (95%-CI) in €
	Intervention	Control	
Direct costs			
Primary care	340 (26)	405 (26)	-65 (-134;-2)
Secondary care	478 (228)	229 (42)	249 (58;515)
Alternative care	742 (218)	322 (55)	421 (182;722)
Medication	29 (7)	44 (9)	-15 (-45;-0.70)
Intervention	70	0	70 (N/A)
Indirect costs			
Absenteeism	1034 (242)	1547 (235)	-513 (-941;-77)
Presenteeism	5735 (681)	6342 (537)	-607 (-2076;-831)
Unpaid productivity	4000 (887)	5047 (616)	-1047 (-1954;-203)
Total societal costs	8444 (820)	8979 (619)	-535 (-2230;1172)

There was no statistically significant difference in QALYs (adjusted for age, gender, educational level, nationality, employment, and physically demanding work) over the 12-month follow-up period between the control and intervention group (adjusted ΔE 0.04; 95%-CI 0.02;0.06). The intervention did not yield significant cost savings (adjusted for age, gender, educational level, nationality, employment, and physically demanding work ΔC € -748 per patient; 95%-CI € -2341;878). The ICER for QALYs was -18,353, which indicates

1
2
3 294 that one QALY gained was associated with a societal cost saving of € 18,353. The majority
4
5 295 (79%) of incremental cost-effectiveness pairs was located in the southeast quadrant of the
6
7 296 cost-effectiveness plane (Figure 3), indicating that the intervention was on average more
8
9 297 effective and less costly. The uncertainty around the cost-effectiveness estimate was large.
10
11
12 298 Figure 4 shows that the intervention has probability of 0.88 of being cost-effective on a
13
14 299 willingness-to-pay of €10.000 per QALY gained, increasing to a probability of 1.00 on a
15
16
17 300 willingness-to-pay of € 80.000 per QALY gained.
18
19
20 301

302 DISCUSSION

303 This study evaluated whether a multifaceted eHealth strategy is effective and cost-effective
304 compared to usual care in improving patients' back pain beliefs and quality of life, and in
305 decreasing their disability and absenteeism. The study results show that the campaign was not
306 effective on these outcomes. The probability of cost-effectiveness was high: 0.88 per QALY
307 gained at a willingness-to-pay threshold of € 10.000, and increased to a maximum probability
308 of 1 per QALY gained at a willingness-to-pay threshold of € 80.000.

309 A possible explanation for the lack of effectiveness might be that in this study, almost 40% of
310 participants did not have back pain anymore at the start of the actual intervention (i.e. baseline
311 moment). Patients who had visited their general practitioner or physiotherapist no longer than
312 3 months prior to recruitment could participate in this study. As a consequence, some patients
313 may have agreed to participate while they had already recovered from their LBP at the start of
314 the intervention. With the recruitment protocol used it was not possible to select only the
315 chronic LBP cases. Therefore, the intervention may no longer have been necessary for the
316 participants that did not have LBP at the start of the intervention, and for them effectiveness
317 was not to be expected. The back beliefs of the study population were quite low at baseline
318 compared to those of the Australian mass media campaign by which the current study was
319 inspired. Mean BBQ scores in the Australian study were 26.5 at the start of the campaign and
320 increased significantly to 29.7, while in the current study the BBQ scores were 24.7 and 24.8
321 in the intervention and control groups, respectively. This indicates that there was room for
322 improvement in back pain beliefs in the current study.^[39] Another study that assessed factors
323 that were associated with beliefs and attitudes of elderly (mean age 69) also found low back
324 pain beliefs scores (mean 23.7).^[40] In the current study disability scores measured with the
325 RDQ-24 showed low levels of disability, and absenteeism rates were also low. Quality of life
326 scores were relatively high and similar between groups with no further improvement over

1
2
3 327 time. It is arguable that the participating patients were in good health states from the start and
4
5 328 gaining much improvement on these functional outcomes was not realistic. Process
6
7 329 evaluations among participating patients and professionals alongside the present study
8
9 330 showed that compliance with the intervention was very low. Most patients did not comply to
10
11 331 the full e-health intervention: 31% of the participants had not used the campaign materials at
12
13 332 all, and 42.9% had only used it once, and professionals almost never discussed the
14
15 333 intervention with their patients. Probably most participants did not need the intervention to
16
17 334 improve their functional ability, but improvement in back pain beliefs could have been
18
19 335 possible had the compliance rates in this study have been higher.^[20-21]

20
21
22
23
24 336 Self-management is recommended for the management of LBP, and healthcare professionals
25
26 337 are advised to provide advice and information, tailored to needs and capabilities, to help
27
28 338 patients self-manage their LBP.^[41] One possible way to help patients self-manage their LBP is
29
30 339 through an eHealth strategy, but evidence regarding the most effective content and mode of
31
32 340 delivery for self-management options is lacking.^[42] eHealth is easy to deliver, safe, and
33
34 341 usually inexpensive (e.g. in the current study, the intervention costs were less than € 70,- per
35
36 342 patient), a recent systematic review on digital support intervention for LBP could not find
37
38 343 significant beneficial effects of digital self-management interventions.^[43] However, most of
39
40 344 the participants in the included studies were Caucasian, highly educated, middle-aged
41
42 345 females, meaning that the findings of the current study are comparable to similar studies. The
43
44 346 results of the current study are in line with other studies that have attempted to improve
45
46 347 patient outcomes and costs in LBP by using multifaceted strategies. A systematic review of
47
48 348 the effectiveness of multifaceted strategies for guideline implementation in LBP and neck
49
50 349 pain did not find that multifaceted strategies changed patient outcomes or costs of care.^[44]
51
52 350 However, the majority of the studies included in the review did not provide insight into the
53
54 351 implementation process, raising the question whether the lack of effectiveness is caused by
55
56
57
58
59
60

1
2
3 352 the failure of the theory (multifaceted strategy) or by failure of the implementation process,
4
5 353 making it difficult to compare the current study to others. It is important to evaluate the
6
7 354 implementation processes in order to truly understand the effectiveness of multifaceted
8
9
10 355 strategies.

11
12
13 356 Another interesting thing to note is the fact that the costs for secondary care and alternative
14
15 357 care are higher in the intervention group than in the control group. This is in line with a very
16
17 358 similar recent implementation study for the management of LBP. In that study, patients in the
18
19 359 intervention group had higher LBP-related costs for inpatient secondary care.^[45] Studies
20
21 360 within and outside the field of LBP research have shown similar results, where patients and
22
23 361 participants in intervention groups show higher costs due to secondary care and/or alternative
24
25 362 care.^[46-50] The literature does not provide explanations for this fact. One explanation could lie,
26
27 363 again, in the low compliance rate of patients in this study.^[20] On the other hand, the use of
28
29 364 alternative care could be seen as self-management, because patients decide what they want,
30
31 365 when they want it, and how much they are willing to pay for it. It could very well be that
32
33 366 patients try self-management through alternative care for a while, and then get referred to
34
35 367 secondary care when and because self-management (through alternative care) did not work
36
37 368 for them. It would be interesting to explore the reasons for the higher costs for secondary care
38
39 369 further.

40
41 370 While the strategy evaluated in this study did not yield (cost)effective results, it might still be
42
43 371 worthwhile considering the possibilities of eHealth interventions from the perspective of
44
45 372 outcomes that were not measured in this study but might have improved, for example actual
46
47 373 self-management. A systematic review of randomised controlled trials that have assessed self-
48
49 374 management education programmes for osteoarthritis found a mismatch between the aims of
50
51 375 such programmes (education and advice about how to self-manage their condition despite
52
53 376 their pain and fears) and how the success of the programmes were assessed.^[51] Many studies

1
2
3 377 have measured health-related outcomes such as pain and function but have not specifically
4
5 378 determined whether the programmes have improved participants' ability to self-manage.
6
7 379 Outcomes such as knowledge about the condition and self-management skills may give more
8
9 380 insight into the value of self-management education programmes and should be considered
10
11 381 essential to measure in future studies evaluating these types of programmes.^[51] Looking at the
12
13 382 cost savings on absenteeism, presenteeism and unpaid productivity losses in the intervention
14
15 383 group compared to the control group, future studies could also benefit from evaluating the
16
17 384 effects and cost-effectiveness of eHealth strategies from employer's perspective.
18
19
20
21

22 385 **Study limitations**

23
24
25 386 The findings of this study must be interpreted with caution. In this study, the loss-to-follow-
26
27 387 up rate was higher for the intervention group (40%) compared to the control group (23%). A
28
29 388 possible explanation could be that the strategy provided too much information and
30
31 389 participants were contacted too often, making them less willing to comply with completion of
32
33 390 the questionnaires over time. The high percentage of loss to follow up may have resulted in a
34
35 391 loss of power and in attrition bias. Furthermore the majority of participants did not need or
36
37 392 use the intervention, and had minimal disability and impaired quality of life at baseline
38
39 393 impacting upon our ability to test the value of our intervention.
40
41
42
43

44 394 **Conclusion**

45
46
47 395 Based on this study, a multifaceted eHealth strategy for patients who had presented to primary
48
49 396 care (i.e. general practice and physiotherapy) with LBP was not effective or cost-effective in
50
51 397 improving back pain beliefs, disability, absenteeism, or quality of life. The multifaceted
52
53 398 eHealth strategy should be studied in a different population, i.e. a more mixed group of
54
55 399 participants in terms of background (e.g. education, nationality), and participants with LBP
56
57 400 and poorer health states at start of the intervention.
58
59
60

1
2
3 401 **FIGURE LEGENDS**
4
5

6 402 Figure 1. Design of the stepped-wedge cluster randomised controlled trial
7
8

9 403 Figure 2. Flow-chart of patient inclusion
10
11

12 404 Figure 3. Cost-effectiveness plane for QALYs
13
14

15 405 Figure 4. CEAC for QALYs
16
17

18
19 406
20
21

22 407
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

408 **REFERENCES**

- 409 1. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low
410 back pain. *Arthritis Rheum* 2012;64(6):2028-37.
- 411 2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional,
412 and national incidence, prevalence, and years lived with disability for 328 diseases and
413 injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of
414 Disease Study 2016. *Lancet* 2017; 390:1211–59.
- 415 3. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates from the
416 Global Burden of Disease 2010 Study. *Ann Rheum Dis* 2014;73:968-974.
- 417 4. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care
418 expenditures among individuals with back pain in the United States. *Spine* 2004;29(1):79–
419 86.
- 420 5. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000;84:95-
421 103.2.
- 422 6. Walker BF, Muller R, Grant WD. Low Back Pain in Australian Adults: The Economic
423 Burden. *Asia Pac J Public Health* 2003;15(2):79-87.
- 424 7. RIVM Kosten van ziekten database 2013. Kosten van zorg voor nek- en rugklachten. (In
425 English: Cost of care for neck- and back pain). Accessed 26-07-2017 through
426 [https://www.volksgezondheidenzorg.info/onderwerp/nek-en-
427 rugklachten/kosten/kosten#node-kosten-van-zorg-voor-nek-en-rugklachten](https://www.volksgezondheidenzorg.info/onderwerp/nek-en-rugklachten/kosten/kosten#node-kosten-van-zorg-voor-nek-en-rugklachten).
- 428 8. Lambeek LC, Van Tulder MW, Swinkels CS, Koppes LLJ, Anema JR, Van Mechelen W.
429 The Trend in Total Cost of Back Pain in the Netherlands in the Period 2002 to 2007.
430 *Spine* 2011;36(13):1050-58.

- 1
2
3 431 9. Ki Ng S, Cicuttini FM, Wang Y, Wluka AE, Fitzgibbon B, Urquhart DM. Negative
4
5 432 beliefs about low back pain are associated with persistent high intensity low back pain.
6
7 433 Psychology, Health & Medicine 2017; 22(7):790-799.
8
9
10 434 10. Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear
11
12 435 avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back
13
14 436 pain: a systematic review. The Spine Journal 2014;14(5):816-836.e4.
15
16
17 437 11. Main CJ, Foster N, Buchbinder R. How important are back pain beliefs and expectations
18
19 438 for satisfactory recovery from back pain? Best Practice & Research Clinical
20
21 439 Rheumatology 2010; 24(2):205-2017.
22
23
24 440 12. Ferreira ML, Machado G, Latimer J, Maher C, Ferreira PH, Smeets RJ. Factors defining
25
26 441 care-seeking in low back pain—a meta-analysis of population based surveys. Eur J Pain
27
28 442 2010;14(7):747.e1-7.
29
30
31 443 13. Wong JJ, Côteé P, Sutton DA, et al. Clinical practice guidelines for the noninvasive
32
33 444 management of low back pain: A systematic review by the Ontario Protocol for Traffic
34
35 445 Injury Management (OPTIMA) Collaboration. Eur J Pain 2016;21:201-216.
36
37
38 446 14. Huber M, Van Vliet M, Giezenberg M, Knottneurs JA. Towards a conceptual framework
39
40 447 relating to ‘Health as the ability to adapt and to self-manage’, Operationalisering
41
42 448 gezondheidsconcept. Driebergen: Louis Bolk Instituut; 2013.
43
44
45 449 15. Du S, Hu L, Dong J, et al. Self-management program for chronic low back pain: A
46
47 450 systematic review and meta-analysis. Patient Education and Counseling 2017;100(1):37-
48
49 451 49.
50
51
52 452 16. Elbert NJ, Van Os-Medendorp H, Van Renselaar W, et al. Effectiveness and cost-
53
54 453 effectiveness of eHealth interventions in somatic diseases: a systematic review of
55
56 454 systematic reviews and meta-analyses. J Med Internet Res 2014; 16(4):e110.
57
58
59
60

- 1
2
3 455 17. McLean S, Chandler D, Nurmatov U, et al. Telehealthcare for asthma. Cochrane Database
4
5 456 Syst Rev 2010(10):CD007717.
6
7
8 457 18. Suman A, Schaafsma FG, Elders PJ, van Tulder MW, Anema JR. Cost-effectiveness of a
9
10 458 multifaceted implementation strategy for the Dutch multidisciplinary guideline for
11
12 459 nonspecific low back pain: design of a stepped-wedge cluster randomised controlled trial.
13
14 460 BMC Public Health 2015;15:522; doi: 10.1186/s12889-015-1876-1.
15
16
17 461 19. Buchbinder R, Jolley D, Wyatt M: 2001 Volvo Award Winner in Clinical Studies: Effects
18
19 462 of a Media Campaign on Back Pain Beliefs and Its Potential Influence on Management of
20
21 463 Low Back Pain in General Practice. Spine. 2001;26(23):2535-2542.
22
23
24 464 20. Suman A, Schaafsma FG, Bamarni J, van Tulder MW, Anema JR. A multimedia
25
26 465 campaign to improve back beliefs in patients with non-specific low back pain: a process
27
28 466 evaluation. BMC Musculoskelet Disord 2017; 18;18(1):200.
29
30
31 467 21. Suman A, Schaafsma FG, Buchbinder R, van Tulder MW, Anema JR. Implementation of
32
33 468 a Multidisciplinary Guideline for Low Back Pain: Process-Evaluation Among Health Care
34
35 469 Professionals. J Occup Rehabil 2017; 27(3):422-433.
36
37
38 470 22. Symonds TL, Burton AK, Tillotson KM, Main CJ. Do attitudes and beliefs influence work
39
40 471 loss due to low back trouble? Occup Med 1996;46(1):25-32.
41
42
43 472 23. Bostick GP, Schopflocher D, Gross DP. Validity evidence for the back beliefs
44
45 473 questionnaire in the general population. Eur J Pain 2013;17(7):10745-
46
47 474 81;doi:10.1002/j.1532-2149.2012.00275.x.
48
49 475 24. Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and the Oswestry
50
51 476 Disability Questionnaire. SPINE 2000;25(24):3115-3124.
52
53
54 477 25. Brooks, R. EuroQol: The current state of play. Health Policy 1996;37:53–72.
55
56
57
58
59
60

- 1
2
3 478 26. Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for
4
5 479 economic evaluation studies. *Expert Review of Pharmacoeconomics & Outcomes*
6
7 480 *Research* 2005;5(1).
8
9
10 481 27. Bouwmans C, De Jong K, Timman R, et al. Feasibility, reliability and validity of a
11
12 482 questionnaire on healthcare consumption and productivity loss in patients with a
13
14 483 psychiatric disorder (TiC-P). *BMC Health Services Research*.
15
16 484 2013;13:217;doi:10.1186/1472-6963-13-217.
17
18
19 485 28. Lamers LM, McDonnell J, Krabbe PFM, van Busschbach JJ. Kwaliteit van leven in
20
21 486 economische evaluaties: het Nederlands EQ-5D tarief. *Ned Tijdschr Geneeskd*
22
23 487 2005;149:1574-78.
24
25
26 488 29. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de
27
28 489 gezondheidszorg. Diemen: Zorginstituut; 2016
29
30
31 490 30. Z-Index. G-standard. The Hague: Z-Index BV; 2009.
32
33 491 31. Groenwold R, Donders AR, Roes K, Harrell F, Moons K. Dealing with missing outcome
34
35 492 data in randomized trials and observational studies. *Am J Epidemiol* 2012;175:210-7.
36
37
38 493 32. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in
39
40 494 epidemiological and clinical research: potentiation and pitfalls. *BMJ* 2009;338:b2393.
41
42 495 33. Twisk JWR. *Applied multilevel analysis: a practical guide for medical researchers*.
43
44 496 Cambridge: Cambridge University Press; 2006.
45
46
47 497 34. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and
48
49 498 guidance for practice. *Stat Med* 2011;30:377-99.
50
51 499 35. Rubin D. *Multiple imputation for nonresponse in surveys*. Hoboken, New Jersey: John
52
53 500 Wiley & Sons; 2004.
54
55
56 501 36. Willian A, Briggs A, Hock J. Regression methods for covariate adjustment and subgroup
57
58 502 analysis for non-censored cost-effectiveness data. *Health Economics* 2004;13:461-75.
59
60

- 1
2
3 503 37. Black W. The CE plane: a graphic representation of cost-effectiveness. *Med Dec Making*
4
5 504 1990;10:212-14.
6
7
8 505 38. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies
9
10 506 and frequently asked questions. *Health Economics* 2004;13:405-15.
11
12 507 39. Buchbinder R, Jolley D, Wyatt M. Population based intervention to change back pain
13
14 508 beliefs and disability: three part evaluation. *BMJ* 2001;322(7301):1516-1520.
15
16
17 509 40. Teixeira LF, Pereira LS, Silva SL, Dias JM, Dias RC. Factors associated with attitudes
18
19 510 and beliefs of elders with acute low back pain: data from the study Back Complaints in the
20
21 511 Elders (BACE). *Braz J Phys Ther* 2016;20(6):553-560;doi:10.1590/bjpt-rbf.2014.0188.
22
23
24 512 41. National Institute for HealthCare Excellence (NICE). 2016. Low back pain and sciatica in
25
26 513 over 16s: assessment and management. NICE guideline [NG59]. Accessed 19-01-2018
27
28 514 through <https://www.nice.org.uk/guidance/ng59>.
29
30
31 515 42. Oliveira VC, Ferreira PH, Maher CG, Pinto RZ, Refshauge KM, Ferreira ML.
32
33 516 Effectiveness of self-management of low back pain: systematic review with meta-analysis.
34
35 517 *Arthritis Care & Research* 2012;64(11):1739-1748.
36
37
38 518 43. Nicholl BI, Sandal LF, Stochkendahl MJ, et al. Digital support interventions for the self-
39
40 519 management of low back pain: a systematic review. *Journal of Medical Internet Research*
41
42 520 2017;19(5):e179.
43
44
45 521 44. Suman A, Dikkers MF, Schaafsma FG, Van Tulder MW, Anema JR.. Effectiveness of
46
47 522 multifaceted implementation strategies for the implementation of back and neck pain
48
49 523 guidelines in health care: a systematic review. *Implementation Science*
50
51 524 2016;11:126;doi:10.1186/s13012-016-0482-7.
52
53
54 525 45. Jensen CE, Riis A, Petersen KD, Jensen MB, Pedersen KM. Economic evaluation of an
55
56 526 implementation strategy for the management of low back pain in general practice. *Pain*
57
58 527 2017;158(5):891-899.
59
60

- 1
2
3 528 46. Lammerts L, Van Dongen JM, Schaafsma FG, Van Mechelen W, Anema JR. A
4
5 529 participatory supportive return to work program for workers without an employment
6
7 530 contract, sick-listed due to a common mental disorder: an economic evaluation alongside a
8
9 531 randomized controlled trial. *BMC Public Health* 2017;17:162;doi:10.1186/s12889-017-
10
11 532 4079-0.
12
13
14 533 47. Noben C, Vilsteren MV, Boot C, et al. Economic evaluation of an intervention program
15
16 534 with the aim to improve at-work productivity for workers with rheumatoid arthritis. *J*
17
18 535 *Occup Health* 2017;59(3):267-279.
19
20
21 536 48. Van der Meer EW, Van Dongen JM, Boot CR, Van der Gulden JW, Bosmans JE, Anema
22
23 537 JR. Economic evaluation of a multifaceted implementation strategy for the prevention of
24
25 538 hand eczema among healthcare workers in comparison with a control group: the Hands4U
26
27 539 study. *Acta Derm Venereol* 2016;96(4):499-504.
28
29
30 540 49. Van Oostrom SH, Heymans MW, De Vet HCW, Van Tulder MW, Van Mechelen M,
31
32 541 Anema JR. Economic evaluation of a workplace intervention for sick-listed employees
33
34 542 with distress. *Occupational and Environmental Medicine* 2010;67:603-610.
35
36
37 543 50. Van der Roer N, Van Tulder M, Van Mechelen W, De Vet H. Economic evaluation of an
38
39 544 intensive group training protocol compared with usual care physiotherapy in patients with
40
41 545 chronic low back pain. *Spine* 2008;33(4):445-51.
42
43
44 546 51. Kroon FP, Van der Burg LR, Buchbinder R, Osborne RH, Johnston RV, Pitt V. Self-
45
46 547 management education programmes for osteoarthritis. *Cochrane Database Syst Rev*
47
48 548 2014;15(1): CD008963.
49
50
51
52
53
54
55
56
57
58
59
60

	T0	T1	T2	T3	T4
Cluster 1	Control	Intervention	Intervention	Intervention	Intervention
Cluster 2	Control	Control	Intervention	Intervention	Intervention
Cluster 3	Control	Control	Control	Intervention	Intervention
Cluster 4	Control	Control	Control	Control	Intervention

Figure 1. Design of the stepped-wedge cluster randomised controlled trial




Figure 2. Flow-chart of patient inclusion

Figure 3. Cost-effectiveness plane for QALYs




Figure 4. CEAC for QALYs




Table 1: CONSORT 2010 checklist of information to include when reporting a cluster randomised trial

Section/Topic	Item No	Standard Checklist item	Extension for cluster designs	Page No *
Title and abstract				
	1a	Identification as a randomised trial in the title	Identification as a cluster randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) ^{1,2}	See table 2	3
Introduction				
Background and objectives	2a	Scientific background and explanation of rationale	Rationale for using a cluster design	5-6
	2b	Specific objectives or hypotheses	Whether objectives pertain to the cluster level, the individual participant level or both	6
Methods				
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Definition of cluster and description of how the design features apply to the clusters	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons		N/A
Participants	4a	Eligibility criteria for participants	Eligibility criteria for clusters	7
	4b	Settings and locations where the data were collected		7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Whether interventions pertain to the cluster level, the individual participant level or both	8-9
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and	Whether outcome measures pertain to the cluster level, the individual participant level or both	9-11

		when they were assessed		
	6b	Any changes to trial outcomes after the trial commenced, with reasons		N/A
Sample size	7a	How sample size was determined	Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or <i>k</i>), and an indication of its uncertainty	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines		N/A
Randomisation:				
Sequence generation	8a	Method used to generate the random allocation sequence		8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Details of stratification or matching if used	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Replace by 10a, 10b and 10c	N/A
	10a		Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions	8
	10b		Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete	8

		enumeration, random sampling)		
	10c		From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how		N/A
	11b	If relevant, description of the similarity of interventions		N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	How clustering was taken into account	11-12
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		11-12
Results				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome	13-14
	13b	For each group, losses and exclusions after randomisation, together with reasons	For each group, losses and exclusions for both clusters and individual cluster members	13-19
Recruitment	14a	Dates defining the periods of recruitment and follow-up		13
	14b	Why the trial ended or was stopped		N/A
Baseline data	15	A table showing baseline demographic and clinical	Baseline characteristics for the individual and cluster levels as	15-17

		characteristics for each group	applicable for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	For each group, number of clusters included in each analysis	15-17
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for each primary outcome	15-17
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		15-17
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		17-19
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms ³)		N/A
Discussion				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		20-23
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Generalisability to clusters and/or individual participants (as relevant)	20-23
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		2-23
Other information				
Registration	23	Registration number and		7

		name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	7
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	25

* Note: page numbers optional depending on journal requirements

For peer review only

Table 2: Extension of CONSORT for abstracts^{1,2} to reports of cluster randomised trials

Item	Standard Checklist item	Extension for cluster trials
Title	Identification of study as randomised	Identification of study as cluster randomised
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)	
Methods		
Participants	Eligibility criteria for participants and the settings where the data were collected	Eligibility criteria for clusters
Interventions	Interventions intended for each group	
Objective	Specific objective or hypothesis	Whether objective or hypothesis pertains to the cluster level, the individual participant level or both
Outcome	Clearly defined primary outcome for this report	Whether the primary outcome pertains to the cluster level, the individual participant level or both
Randomization	How participants were allocated to interventions	How clusters were allocated to interventions
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	
Results		
Numbers randomized	Number of participants randomized to each group	Number of clusters randomized to each group
Recruitment	Trial status ¹	
Numbers analysed	Number of participants analysed in each group	Number of clusters analysed in each group
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision	Results at the cluster or individual participant level as applicable for each primary outcome
Harms	Important adverse events or side effects	
Conclusions	General interpretation of the results	
Trial registration	Registration number and name of trial register	
Funding	Source of funding	

¹ Relevant to Conference Abstracts

REFERENCES

- 1 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 2008, 371:281-283
- 2 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 5(1): e20
- 3 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004; 141(10):781-788.

For peer review only

CHEERS checklist—Items to include when reporting economic evaluations of health interventions

Section/item	Item No	Recommendation	Reported on page No/ line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	P. 1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	P. 3
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	P. 5 - 6
		Present the study question and its relevance for health policy or practice decisions.	P. 5 - 6
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	P. 7
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	P. 7
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	P. 7 - 12
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	P. 8 - 9
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	P. 7 - 12
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	N/A
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	P. 9 - 11
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	P. 9 - 12
	11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	N/A
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	N/A
Estimating resources and costs	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	P. 10 – 12
	13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate	N/A

Section/item	Item No	Recommendation	Reported on page No/ line No
		resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	P. 10 – 12
Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	P. 10 – 12
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	P. 10 – 12
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	P. 11 – 12
Results			
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	P. 17 – 19
Incremental costs and outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	P. 18 – 19
Characterising uncertainty	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).	P. 18 – 19
	20b	<i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	N/A
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	N/A
Discussion			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	P. 20 – 23
Other			
Source of funding	23	Describe how the study was funded and the role of	P. 25

Section/item	Item No	Recommendation	Reported on page No/ line No
		the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	P. 24

For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist

For peer review only

BMJ Open

Effectiveness and cost-utility of a multifaceted eHealth strategy to improve back pain beliefs of patients with nonspecific low back pain: a cluster randomised trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030879.R1
Article Type:	Original research
Date Submitted by the Author:	24-Oct-2019
Complete List of Authors:	Suman, Arnela; Amsterdam UMC - Locatie VUMC; University of Alberta, Faculty of Rehabilitation Medicine, Department of Physical Therapy Schaafsma, F; Amsterdam UMC - Locatie VUMC van Dongen, Johanna M.; Vrije Universiteit Amsterdam Elders, Petra; Amsterdam UMC - Locatie VUMC Buchbinder, Rachelle; Monash University Tulder, Maurits; Vrije Universiteit Amsterdam Anema, Johannes; Amsterdam UMC - Locatie VUMC
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology, General practice / Family practice, Health economics
Keywords:	LOW BACK PAIN, RANDOMIZED CONTROLLED TRIAL, E-HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS

SCHOLARONE™
Manuscripts

1
2
3 **1 Effectiveness and cost-utility of a multifaceted eHealth strategy to improve back pain**
4
5 **2 beliefs of patients with nonspecific low back pain: a cluster randomised trial**
6
7
8
9 **3**

10
11 4 Arnela Suman, Frederieke G. Schaafsma, Johanna M van Dongen, Petra JM Elders, Rachelle
12
13 5 Buchbinder, Maurits W van Tulder, Johannes R Anema
14
15
16
17 **6**

18
19
20 7 Arnela Suman, Amsterdam UMC, VU University Amsterdam, department of Public and
21
22 8 Occupational Health, Amsterdam Public Health research institute, De Boelelaan 1117, 1081HV
23
24 9 Amsterdam, The Netherlands
25
26
27
28 **10**

29
30
31 11 Corresponding author: Frederieke G Schaafsma, Amsterdam UMC, VU University
32
33 12 Amsterdam, department of Public and Occupational Health, Amsterdam Public Health research
34
35 13 institute, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands; f.schaafsma@vumc.nl;
36
37 14 0031-20-4445685
38
39
40
41 **15**

42
43
44 16 Johanna M van Dongen, VU University Amsterdam, department of Health Sciences,
45
46 17 Amsterdam Public Health research institute, Amsterdam, The Netherlands
47
48
49
50 **18**

51
52
53 19 Petra JM Elders, Amsterdam UMC, VU University Amsterdam, department of General Practice
54
55 20 and Elderly Care, Amsterdam Public Health research institute, Amsterdam, The Netherlands
56
57
58
59
60

1
2
3 21 Rachelle Buchbinder, Monash Department of Clinical Epidemiology, Cabrini Institute and
4
5 22 Department of Epidemiology and Preventive Medicine, School of Public Health & Preventive
6
7 23 Medicine, Monash University, Victoria, Australia
8
9

10
11 24
12

13
14 25 Maurits W van Tulder, VU University Amsterdam, department of Health Sciences Amsterdam
15
16 26 Public Health research institute, Amsterdam, The Netherlands
17
18

19 27
20

21
22 28 Johannes R Anema, Amsterdam UMC, VU University Amsterdam, department of Public and
23
24 29 Occupational Health, Amsterdam Public Health research institute, Amsterdam, The
25
26 30 Netherlands
27
28

29
30 31
31

32 32 Word count: 4356
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **33 ABSTRACT**
4
5

6 **34 Objectives** To assess the effectiveness and cost-utility of a multifaceted eHealth strategy
7
8
9 **35** compared to usual care in improving patients' back pain beliefs, and in decreasing disability
10
11 **36** and absenteeism.

12
13
14 **37 Design** A stepped-wedge cluster randomized trial with parallel economic evaluation.
15

16
17 **38 Setting** Dutch primary health care.
18

19
20 **39 Participants** Patients diagnosed with nonspecific low back pain by their general practitioner or
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40 physiotherapist. Patients with serious comorbidities or confirmed pregnancy were excluded.
41 779 patients were randomised into intervention group (n=331, 59% female; 60.4% completed
42 study) or control group (n=448, 57% female; 77.5% completed study).

43 Interventions The intervention consisted of a multifaceted eHealth strategy that included a
44 (mobile) website, digital monthly newsletters, and social media platforms. The website
45 provided information about back pain, practical advice (e.g. on self-management), working and
46 returning to work with back pain, exercise tips, and short video messages from healthcare
47 providers and patients providing information and tips. The control consisted a digital patient
48 information letter. Patients and outcome assessors were blinded to group allocation.

49 Primary and secondary outcome measures The primary outcome was back pain beliefs.
50 Secondary outcome measures were disability and absenteeism, and for the pre-planned
51 economic evaluation quality of life and societal costs were measured.

52 Results There were no between-group differences in back pain beliefs, disability, or
53 absenteeism. Mean intervention costs were € 70,- and the societal cost difference was € 535,-
54 in favour of the intervention group, but no significant cost savings were found. The ICER

1
2
3 55 indicated that the intervention dominated usual care and the probability of cost-effectiveness
4
5 56 was 0.85 on a willingness-to-pay of € 10,000/QALY.
6
7

8
9 57 **Conclusions** A multifaceted eHealth strategy was not effective in improving patients' back pain
10
11 58 beliefs or in decreasing disability and absenteeism, but showed promising cost-utility results
12
13 59 based on QALYs.
14
15

16 60 **Trial registration** Netherlands Trial Register (NTR), number: NTR4329.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

62 **Strengths and limitations of this study**

- 63 • Robust study design: stepped-wedge cluster randomised controlled trial
- 64 • Comprehensive, multifaceted e-Health strategy for low back pain
- 65 • Effectiveness and cost-utility evaluated
- 66 • High rate of loss to follow-up in intervention group (40%) compared to control group (23%)

68 **Funding statement**

69 This study was funded by the Netherlands Organisation for Health Research and Development
70 (ZonMw), grant number 80-83700-98-133053.
71
72

72 **Competing Interests**

73 All authors have completed the ICMJE uniform disclosure form at
74 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
75 submitted work (other than funding agency); no financial relationships with any organisations
59
60

1
2
3 76 that might have an interest in the submitted work in the previous three years; no other
4
5 77 relationships or activities that could appear to have influenced the submitted work.
6
7
8
9 78

10 11 79 **Authors Statement**

12
13
14
15 80 AS collected, prepared, and analysed data and prepared the manuscript. JMvD assisted in cost-
16
17 81 utility analyses, interpreted data, and revised the manuscript. FGS, PJME, RB, MWvT, and
18
19 82 JRA were all involved in design of the study, interpretation of data, and revising the manuscript
20
21
22 83 for intellectual content.
23
24
25 84

26 27 28 85 **Data sharing**

29
30
31 86 Relevant data are available upon reasonable request.
32
33
34 87

88 BACKGROUND

89 Low back pain (LBP) is a major medical problem throughout the world. The global 1-month
90 point prevalence is estimated to be 23.2%.^[1] LBP is the leading cause of musculoskeletal and
91 work disability, and years lived with disability (YLDs) worldwide.^[2-3] Recent estimates from
92 the Global Burden of Disease Study indicate that LBP accounts for 57 million YLDs, and that
93 over 250 million people develop LBP annually.^[2] The economic burden of LBP is high.
94 Estimates of the annual economic burden of LBP vary from between AU\$9.17 billion in
95 Australia, £12.3 billion in the UK, and US\$91 billion in the United States.^[4-6] In the
96 Netherlands, recent estimates report the costs of LBP to be around €1.3 billion, a quarter of all
97 healthcare costs due to musculoskeletal disorders.^[7] However, indirect costs due to absenteeism
98 and to reduced productivity while at work are not included in this estimate. Previous research
99 has shown that indirect costs make up 88% of all societal costs due to LBP.^[8] Since LBP leads
100 to a high proportion of work absence, the costs of LBP in the Netherlands are much higher than
101 suggested.^[7] Besides the burden on society, LBP has a high burden on the lives of individuals.
102 Over the past decades, several studies have shown that people with negative back pain beliefs
103 have more pain, disability, negative work-related outcomes (i.e. productivity loss and sickness
104 absence), and higher health care utilization.^[9-12]

105 Many guidelines for LBP recommend self-management for patients, which is a reflection of a
106 newly proposed definition of health, i.e. “health as the ability to adapt and self-manage.”^[13-14] A
107 systematic review on the effectiveness of education programmes designed to improve self-
108 management suggested that these programmes are effective in improving pain intensity and
109 disability, but did not measure actual self-management.^[15]

110 Underlined by the high economic, societal, and individual burden of LBP, no highly effective
111 treatment for LBP has yet been found. However, eHealth, which is the provision of
112 (personalised) health care at a distance (e.g. through internet and thus digital), has shown

1
2
3 113 promise with regards to its' effectiveness and cost-effectiveness in improving outcomes such
4
5 114 as patient health, patient satisfaction, self-management and healthcare costs in patients with
6
7 115 physical diseases.^[16-17] Therefore, the current study aimed to assess the effectiveness and cost-
8
9 116 utility of a multifaceted eHealth strategy to improve beliefs, knowledge, and self-management
10
11 117 of LBP compared to usual care in improving patients' back pain beliefs, and in decreasing their
12
13
14 118 disability and absenteeism.
15
16
17
18 119

For peer review only

120 **METHODS**

121 **Study design**

122 This study was part of a cluster-randomised controlled trial with a pre-planned parallel
123 economic evaluation, that was registered in 2013 with the Netherlands Trial Register (NTR)
124 under number NTR4329.^[18] The trial lasted from September 2013 to September 2017, with the
125 actual intervention being provided between April 2014 and December 2016. The Medical
126 Ethics Committee of the VU University medical centre assessed this study's design and
127 procedures, and in accordance with the local regulatory guidelines and standards for human
128 subjects protection in the Netherlands (Medical Research Involving Human Subjects Act
129 [WMO], 2005), this study proved to be exempt from further medical ethical review. A detailed
130 description of the design of this study has been published elsewhere.^[18] This study is reported
131 following the Consort statement (Supplementary file 1) and the Cheers statement
132 (Supplementary file 2).

133 **Participants**

134 Twenty-five general practices, 19 physiotherapy practices, and 29 occupational physicians in
135 the Amsterdam area participated in this study and recruited patients for this trial. Patients were
136 aged 18-75 years and were diagnosed with nonspecific LBP by their general practitioner (GP)
137 or physiotherapist (PT), whom they had visited due to back complaints no longer than 3 months
138 prior to inclusion in the study. Nonspecific LBP was defined as LBP with or without motor
139 and/or sensory deficits in one or both legs, including sciatica and radiculopathy, that is not
140 caused by underlying specific pathology (red flags), i.e. a tumour, (osteoporotic) vertebral
141 fracture, ankylosing spondylitis, and cauda equina syndrome. Exclusion criteria were: serious
142 comorbidities including Alzheimer's disease, multiple sclerosis, Parkinson's disease,
143 amyotrophic lateral sclerosis, cerebrovascular accident in the last year, malignancy in the last

1
2
3 144 five years, and severe psychiatric disorders, i.e. schizophrenia and bipolar disorder. Patients
4
5 145 with confirmed pregnancy in the last year were also excluded. Assessment of exclusion criteria
6
7 146 was done electronically using software, as well as manual assessment by the referring general
8
9 147 practitioner or physiotherapist.

13 148 **Randomisation**

16 149 This study was a stepped-wedge cluster randomised controlled trial. The participating general
17
18 150 practices, physiotherapy practices, and occupational physicians were assigned to one of four
19
20 151 clusters based on their geographic proximity to each other. The clusters sequentially received a
21
22 152 multifaceted continuing medical education training (illustrated by Figure 1). This clustering
23
24 153 allowed for minimisation of contamination between the participants. Patients were allocated
25
26 154 according to the group their general practitioner, physiotherapist or occupational physician were
27
28 155 assigned, i.e., patients registered within a practice that was in the control group at time of
29
30 156 enrolment were allocated to the control group for patients, thus randomisation and allocation
31
32 157 were performed on cluster level. However, patients were blinded and not aware of group
33
34 158 allocation, and thus concealment was on individual level. Randomisation was performed by
35
36 159 means of computer-generated allocation, using specific software. An independent research
37
38 160 assistant performed the concealed allocation, enrolling of participants, and assignment of
39
40 161 participants to groups. Outcome assessors were blinded to individual patient allocation.

47 162 **Intervention and control**

50 163 The intervention was provided to patients on an individual level. Patients in the cluster whose
51
52 164 GP or PT was randomised into the intervention group received access to a multifaceted eHealth
53
54 165 strategy that aimed to reduce patients' negative back pain beliefs and improve their knowledge
55
56 166 and self-management of LBP. The campaign included an informative website, digital monthly
57
58 167 newsletters, and social media platforms. The website provided comprehensive information
59
60

1
2
3 168 about LBP, such as practical advice (e.g. on self-management), working and returning to work
4
5 169 with LBP, exercise tips, and short video messages. In these videos, actors and healthcare
6
7 170 professionals shared their experiences with LBP and provided tips on self-management, coping,
8
9 171 and working with LBP. The videos were inspired by the effective Australian mass media
10
11 172 campaign ‘Back Pain: Don’t Take It Lying Down’.^[19] Social media platforms included a forum
12
13 173 on the website, and a Facebook page where patients could contact researchers, healthcare
14
15 174 providers, and other patients. All parts of the intervention were also available in a mobile
16
17 175 version that was adaptive to any electronic device. Patients were required to use pre-set
18
19 176 usernames and passwords to enter the intervention website. The patient intervention was
20
21 177 supported by continuing medical education for GPs, PTs, and occupational physicians (OPs).
22
23 178 More detailed descriptions of the patient and professional based interventions are published
24
25 179 elsewhere.^[20-21] Patients in the control group received a digital patient information letter and
26
27 180 had no access to the intervention website, materials or social media platforms. Results of the
28
29 181 professional based intervention have been published elsewhere.^[22]
30
31
32
33
34
35

36 182 **Sample size and outcomes**

37
38
39 183 The primary outcome measure was back pain beliefs, assessed using the Back Beliefs
40
41 184 Questionnaire (BBQ). The BBQ is designed to measure beliefs about the inevitable
42
43 185 consequences of LBP (e.g. there is no real treatment for back trouble, back trouble must be
44
45 186 rested). It is a validated questionnaire consisting of 14 items, and rates back pain beliefs on a
46
47 187 scale of 9 to 45, with higher scores indicating more positive (better) back pain beliefs (e.g.
48
49 188 exercising through LBP is good).^[23-24]
50
51
52
53

54 189 The sample size calculation was based on a hypothesized 10% improvement in back pain beliefs
55
56 190 as measured by the BBQ, based on an observed mean improvement of 9.6% between three
57
58 191 successive surveys in the Australian campaign.^[19] An intra-class correlation coefficient (ICC)
59
60

1
2
3 192 of 0.05 was applied to adjust for the cluster randomisation design. Assuming a 10%
4
5 193 improvement from a mean score of 26.5 (95% Confidence Interval (CI) 26.1-26.8, SD 6) on the
6
7 194 BBQ, and applying an ICC of 0.05, the necessary sample size was estimated to be 500 patients.
8
9
10 195 This calculation takes into account a dropout-rate of 20%, power (1-beta) of 0.90 and an alpha
11
12 196 of 0.05.

13
14
15 197 The secondary outcomes included disability, measured with the Roland Disability
16
17 198 Questionnaire (RDQ-24), which has been shown to be a valid and reliable instrument for
18
19 199 patients with LBP.^[25] The RDQ-24 consists of 24 items, rating disability on a scale of 0 to 24,
20
21 200 with higher scores indicating more disability. The EQ-5D-3L was used to measure quality of
22
23 201 life for the purpose of the economic evaluation.^[26] Health care use, absenteeism, presenteeism
24
25 202 and unpaid productivity losses were measured with the generic PROductivity and DIsease
26
27 203 Questionnaire (PRODISQ) and the Trimbos/iMTA questionnaire for Costs associated with
28
29 204 Psychiatric Illness (TIC-P).^[27-28] Resource use data was collected using 3-month recall periods.
30
31 205 All outcomes were measured at baseline and after 3, 6, and 12 months follow-up. The study
32
33 206 protocol initially included measuring the level of pain using the Pain Coping Inventory (PCI)
34
35 207 questionnaire. However, as this questionnaire proved to put an unreasonable (time) burden on
36
37 208 the patients, it was no longer used and measured. Instead, having back pain at baseline was
38
39 209 measured and reported.

40
41
42
43
44
45
46 210 For the economic evaluation, the scores on the EQ-5D-3L were converted into utility scores
47
48 211 using the Dutch tariff.^[29] These utility scores range from 0 (death) to 1 (maximum health.
49
50 212 Quality adjusted life years (QALYs) were calculated using linear interpolation between
51
52 213 measurement points.

53
54
55
56 214 Societal costs are the sum of intervention costs, costs for the use of healthcare, and costs for
57
58 215 informal care (i.e. care provided by family and other volunteers), work absenteeism,
59
60

1
2
3 216 presenteeism (i.e. reduced productivity at work), and unpaid productivity losses (i.e. reduced
4
5 217 productivity in unpaid activities, such as volunteer work). The intervention costs comprised all
6
7 218 costs related to the development and implementation of the intervention (Supplementary file
8
9
10 219 3). Intervention costs were micro-costed, meaning that detailed data were collected on the
11
12 220 number of resources consumed as well as their associated unit prices (Supplementary file 4
13
14 221 shows unit costs). Information on the costs of materials was collected from a detailed overview
15
16 222 of project budget expenditures. The time investments of the intervention providers were costed
17
18 223 using estimates of their gross hourly salaries. There were no costs for the intervention for the
19
20 224 control group. Healthcare utilization included primary healthcare (e.g. GP, PT), secondary
21
22 225 healthcare (e.g. diagnostic imaging, medical specialist), alternative healthcare (e.g. acupuncture
23
24 226 or massage), and medication (both prescribed and over-the-counter medication related to LBP).
25
26 227 To value healthcare utilization, prices from the Dutch Manual for Costing (DMC) were used.^[30]
27
28 228 Where standard costs were unavailable, prices provided by healthcare professionals'
29
30 229 associations were used. Medication use was valued using the prices of the Royal Dutch Society
31
32 230 of Pharmacy.^[31] Informal care was valued using a recommended Dutch shadow price according
33
34 231 to the DMC.^[30] Absenteeism was calculated and valued using patient data collected with the
35
36 232 PRODISQ and TIC-P. In accordance with the DMC, patients' daily absenteeism cost was
37
38 233 calculated by dividing their self-reported gross annual salary by their total number of workable
39
40 234 days per year. Using the Friction Cost Approach (FCA, friction period 23 weeks), absenteeism
41
42 235 costs were estimated by multiplying the total number of sick leave days during follow-up by
43
44 236 their associated costs. Presenteeism was calculated using patient data collected with the TIC-P,
45
46 237 where patients indicated how many days they went to work while having LBP. To obtain
47
48 238 workday equivalents lost to presenteeism, this number of days was multiplied by a self-reported
49
50 239 inefficiency score ranging between 0 (could not perform any tasks) and 1 (could perform all
51
52 240 tasks as efficient as without LBP). Presenteeism costs were subsequently calculated by
53
54
55
56
57
58
59
60

1
2
3 241 multiplying the total number of presenteeism days by their associated costs. All costs were
4
5 242 transformed to 2016 Euros. As follow-up was 12 month, discounting was not necessary.
6
7

8 243 **Statistical analyses**

9
10
11 244 Analyses were performed according to the intention-to-treat principle. Descriptive statistics
12
13
14 245 were used to compare baseline characteristics between intervention and control group
15
16 246 participants as well as between participants with complete and incomplete data. Missing values
17
18 247 for costs and effects were imputed using Multiple Imputation by Chained Equations, and
19
20 248 imputations were performed separately for the intervention and control group.^[32-33] Variables
21
22 249 associated with the “missingness” of data, outcomes and potential confounders were included
23
24 250 in the imputation model. Cost and effect measure values were imputed per time point, costs
25
26 251 were imputed at the cost category level and effects were imputed at the outcome level. Using
27
28 252 predictive mean matching, a total of 10 complete data sets were generated in order for the loss
29
30 253 of efficiency to be below 5% and pooled estimated were calculated according to Rubin’s
31
32 254 rules.^[32-35] Effectiveness analyses were performed using maximum likelihood estimation
33
34 255 longitudinal mixed-effects models with multilevel structure to account for clustering effects,
35
36 256 and ‘missing at random’ assumptions.^[36] Analyses of effect and cost data were performed in
37
38 257 Stata 14, and the statistical significance level was set at $p < 0.05$. Regression coefficients or odds
39
40 258 ratios (ORs) were calculated with 95%-confidence intervals (CIs).
41
42
43
44
45
46

47 259 A cost-utility analysis (CUA) was performed from a societal perspective. Imputation models
48
49 260 included intervention costs, age, gender, educational level, nationality, being employed,
50
51 261 performing physically demanding work, physical activity (minutes per week), and available
52
53 262 cost and effect measure values. Cost and effect difference estimates between intervention and
54
55 263 control group were analysed using seemingly unrelated regression (SUR), while simultaneously
56
57 264 adjusting for the possible correlation between costs and effects.^[37] Incremental cost-
58
59
60

1
2
3 265 effectiveness ratios (ICERs) were calculated by dividing the adjusted mean cost differences by
4
5 266 those in effects. Uncertainty surrounding the cost differences and ICERs was estimated using
6
7 267 Bias Corrected and Accelerated bootstrapping (BCA) with 5000 replications, and presented by
8
9 268 95%-CIs and plotted on cost-effectiveness planes.^[38] Cost-effectiveness acceptability curves
10
11 269 (CEACs) presented the probability of the intervention being cost-effectiveness at different
12
13 270 values of willingness to pay.^[39] A sensitivity analysis was performed, in which only patients
14
15 271 with complete data on all measurement points were included.
16
17
18
19

20 272 **Patient involvement**

21
22
23 273 The Dutch patient association for spinal disorders (“NVV De Wervelkolom”) was involved in
24
25 274 the design of this study and provided advice about the content of the intervention.
26
27
28
29

30 275
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

276 **RESULTS**

277 **Participants**

278 In total, 5181 eligible patients were invited to participate in this study. Of these patients, 779
279 (response rate of 15%) agreed to participate and were randomised to the intervention (n=331)
280 and control (n=448) groups (Figure 2). Follow-up responses in the intervention group were
281 69.8% at 3 months follow-up, 70.1% at 6 months follow-up, and 60.4% at 12 months follow-
282 up. The follow-up responses in the control group were higher than in the intervention group at
283 3 months follow-up (77%) and 12 months follow-up (77.5%). At 6 months follow-up the
284 responses in the control group were similar to those in the intervention group (69.6%).

285 At baseline, characteristics of patients in the intervention group were similar to those in the
286 control group. Table 1 shows that a high percentage of participants were female, 60%
287 (intervention group) and 57% (control group) had a high educational level, and over half of the
288 participants were employed. They performed about 3 hours of physical activity per week. Table
289 1 also shows the baseline scores on the BBQ, RDQ-24, and absenteeism for both groups. At
290 baseline, there was a lower absenteeism rate in the intervention group compared to the control
291 group.

292 Table 1. Baseline characteristics of patients

	Intervention (n=331)	Control (n=448)
Mean age (SD*)	55.7 (13.9) (n=320)	56.6 (14.6) (n=439)
Female gender (%)	188 (59) (n=320)	252 (57) (n=439)
Back pain at baseline (%)	201 (63) (n=320)	275 (63) (n=439)
Nationality (%)	(n=320)	(n=439)
- Dutch	298 (93)	409 (93)
- Western countries immigrant	16 (5)	23 (5)
- Non-western countries immigrant	6 (2)	7 (2)
Educational level (%)	(n=320)	(n=439)
- None (never attended school):	9 (3)	12 (3)
- Lower (primary school)	25 (8)	42 (10)
- Vocational (college)	92 (29)	134 (30)
- Higher (university and university of applied sciences)	194 (60)	251 (57)
Mean activity minutes/week (SD)	161 (109) (n=196)	166 (104) (n=254)
Employed (paid work) (%)	183 (57) (n=320)	232 (53) (n=439)
Physically demanding work (%)	88 (28) (n=320)	121 (28) (n=439)
Mean back pain beliefs score (SD) (measured by BBQ, range 9-45; higher score means more positive back pain beliefs)	24.7 (6.0) (n=295)	24.8 (6.2) (n=394)
Mean disability score (SD) (measured by RDQ-24, range 0-24; higher score means more disability)	5.1 (4.7) (n=317)	5.9 (5.3) (n=434)
Mean absenteeism days (SD) (self-reported number of days over past three months)	2.2 (7.0) (n=187)	4.0 (13.2) (n=246)
Mean quality of life score (SD) (utility score measured by EQ-5D; range 0 to 1; higher score means better quality of life)	0.79 (0.22) (n=331)	0.75 (0.25) (n=448)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

293

294 * SD: Standard Deviation

For peer review only

295 **Intention-to-treat effectiveness analysis**

296 Table 2 shows the mean scores on the BBQ, RDQ-24, absenteeism, and quality of life of the
 297 intervention group compared to the control group. Table 3 shows the results of the intention-
 298 to-treat analysis. There were no significant differences in back pain beliefs, disability and
 299 absenteeism between groups at any time point. The interaction term with gender was significant
 300 for disability, showing that the effect for males was larger than that for females.

301

302 *Table 2. Mean scores (SD) on BBQ, RDQ-24, EQ-5D and absenteeism*

	Mean (SD) back pain beliefs <i>(measured by BBQ, range 9-45; higher score means more positive back pain beliefs)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	24.4 (5.8)	24.0 (5.9)	24.1 (5.8)
Control group	24.9 (6.2)	24.6 (6.0)	24.1 (6.3)
	Mean (SD) disability <i>(measured by RDQ-24, range 0-24; higher score means more disability)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	4.4 (4.7)	3.9 (4.3)	3.9 (4.3)
Control group	5.2 (5.1)	4.8 (4.8)	4.5 (4.7)
	Mean (SD) absenteeism <i>(self-reported number of days over past three months)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	1.2 (6.5)	0.9 (4.8)	0.7 (2.7)

Control group	2.6 (9.8)	0.7 (4.1)	0.7 (4.4)
	Mean (SD) quality of life <i>(utility score measured by EQ-5D; range 0 to 1; higher score means better quality of life)</i>		
	3 months follow-up	6 months follow-up	12 months follow-up
Intervention group	0,857 (0,209)	0,904 (0,163)	0,914 (0,152)
Control group	0,824 (0,236)	0,857 (0,214)	0,866 (0,191)

303 Table 3. Adjusted effects of the intervention based on intention-to-treat analyses

Outcome		Difference between intervention and control	95%-CI
Back pain beliefs¹		-0.13	-0.90;0.65
Disability	Male	-1.13	0.93;1.37
	Female	-0.79	0.68;0.93
Absenteeism^{2;3}		-0.94	0.69;1.29

304 1: Adjusted for educational level, physical activity, having back pain at baseline, being employed, comorbidity;

305 2: Adjusted for age, physical activity, having back pain at baseline; 3: Only for participants who were employed at
306 baseline (intervention group n=183; control group n=232)

307

308

309 Cost-utility analysis

310 Intervention costs per patient were € 70. Direct costs for primary care and medication were
311 lower in the intervention than in the control group, while direct costs for secondary and
312 alternative care were higher in the intervention than in the control group. Indirect costs due to
313 absenteeism, presenteeism, and unpaid productivity loss were lower in the intervention than in
314 the control group. The crude total cost differences were not significant (Table 4).

315

316 *Table 4. Crude costs per cost category in euros (€)*

Cost category	Mean costs (SEM*) in €		Cost difference (95%-CI) in €
	Intervention	Control	
Direct costs			
Primary care	340 (26)	405 (26)	-65 (-134;-2)
Secondary care	478 (228)	229 (42)	249 (58;515)
Alternative care	742 (218)	322 (55)	421 (182;722)
Medication	29 (7)	44 (9)	-15 (-45;-0.70)
Intervention	70	0	70 (N/A)
Indirect costs			
Absenteeism	1034 (242)	1547 (235)	-513 (-941;-77)
Presenteeism	5735 (681)	6342 (537)	-607 (-2076;-831)
Unpaid productivity	4000 (887)	5047 (616)	-1047 (-1954;-203)
Total societal costs	8444 (820)	8979 (619)	-535 (-2230;1172)

317 * SEM: Standard Error of the Mean

318 During the 12-month follow-up, intervention and control group participants gained 0.881
319 (SEM=0.008) and 0.837 (SEM=0.008) QALYs, respectively. There was a statistically
320 significant difference in QALYs (adjusted for age, gender, educational level, nationality,
321 employment, and physically demanding work, and baseline utility value) over the 12-month
322 follow-up period between the control and intervention group (adjusted effect difference 0.03;
323 95%-CI 0.001;0.042). The intervention did not yield significant cost savings (adjusted for age,
324 gender, educational level, nationality, employment, and physically demanding work cost

1
2
3 325 difference € -748 per patient; 95%-CI € -2341;878). The ICER for QALYs indicated that the
4
5 326 intervention dominated usual care. The majority (79%) of incremental cost-effectiveness pairs
6
7 327 was located in the southeast quadrant of the cost-effectiveness plane (Figure 3), indicating that
8
9 328 the intervention was on average more effective and less costly. Figure 4 shows that the
10
11 329 intervention has probability of 0.85 of being cost-effective on a willingness-to-pay of €10.000
12
13 330 per QALY gained, increasing to a probability of 1.00 on a willingness-to-pay of € 80.000 per
14
15 331 QALY gained. Results of the sensitivity analysis differed extensively from those of the main
16
17 332 analysis (adjusted cost difference € 1780 per patient; 95%-CI € -1298 to 6945; adjusted effect
18
19 333 difference -0.002; 95%-CI -0.079 to 0.075), suggesting that the “missingness” of data is likely
20
21
22
23 334 related to various observed factors.
24
25
26
27 335

DISCUSSION

This study evaluated the effectiveness and cost-utility of a multifaceted eHealth strategy compared to usual care in improving patients' back pain beliefs, and in decreasing their disability and absenteeism. The study results show that the campaign was not effective on these outcomes. The probability of cost-effectiveness was high: 0.85 per QALY gained at a willingness-to-pay threshold of € 10.000, and increased to a maximum probability of 1 per QALY gained at a willingness-to-pay threshold of € 80.000.

A possible explanation for the lack of effectiveness might be that in this study, almost 40% of participants did not have back pain anymore at the start of the actual intervention (i.e. baseline moment). Patients who had visited their general practitioner or physiotherapist no longer than 3 months prior to recruitment could participate in this study. As a consequence, some patients may have agreed to participate while they had already recovered from their LBP at the start of the intervention. With the recruitment protocol used it was not possible to select only the chronic LBP cases. Therefore, the intervention may no longer have been necessary for the participants that did not have LBP at the start of the intervention, and for them effectiveness was not to be expected. The back pain beliefs of the study population were quite low at baseline compared to those of the Australian mass media campaign by which the current study was inspired.^[40] Mean BBQ scores in the Australian study were 26.5 at the start of the campaign and increased significantly to 29.7, while in the current study the BBQ scores were 24.7 and 24.8 in the intervention and control groups, respectively. This indicates that there was room for improvement in back pain beliefs in the current study.^[40] Another study that assessed factors that were associated with beliefs and attitudes of elderly (mean age 69) also found low back pain beliefs scores (mean 23.7).^[41] In the current study disability scores measured with the RDQ-24 showed low levels of disability, and absenteeism rates were also low. Quality of life scores were relatively high and similar between groups with no further improvement over time.

1
2
3 361 It is arguable that the participating patients were in good health states from the start and gaining
4
5 362 much improvement on these functional outcomes was not realistic. Process evaluations among
6
7 363 participating patients and professionals alongside the present study showed that compliance
8
9
10 364 with the intervention was very low.^[20-21] Most patients did not comply to the full e-health
11
12 365 intervention: 31% of the participants had not used the campaign materials at all, and 42.9% had
13
14 366 only used it once, and professionals almost never discussed the intervention with their patients.
15
16 367 Probably most participants did not need the intervention to improve their functional ability, but
17
18 368 improvement in back pain beliefs could have been possible had the compliance rates in this
19
20 369 study been higher.^[20-21]
21
22
23
24 370 Self-management is recommended for the management of LBP, and healthcare professionals
25
26 371 are advised to provide advice and information, tailored to needs and capabilities, to help patients
27
28 372 self-manage their LBP.^[42] One possible way to help patients self-manage their LBP is through
29
30 373 an eHealth strategy, but evidence regarding the most effective content and mode of delivery for
31
32 374 self-management options is lacking.^[43] eHealth is easy to deliver, safe, and usually inexpensive
33
34 375 (e.g. in the current study, the intervention costs were less than € 70 per patient), a recent
35
36 376 systematic review on digital support intervention for LBP could not find significant beneficial
37
38 377 effects of digital self-management interventions.^[44] However, most of the participants in the
39
40 378 included studies were Caucasian, highly educated, middle-aged females, meaning that the
41
42 379 findings of the current study are comparable to similar studies. The results of the current study
43
44 380 are in line with other studies that have attempted to improve patient outcomes and costs in LBP
45
46 381 by using multifaceted strategies. A systematic review of the effectiveness of multifaceted
47
48 382 strategies for guideline implementation in LBP and neck pain did not find that multifaceted
49
50 383 strategies changed patient outcomes or costs of care.^[45] However, the majority of the studies
51
52 384 included in the review did not provide insight into the implementation process, raising the
53
54 385 question whether the lack of effectiveness is caused by the failure of the theory (multifaceted
55
56
57
58
59
60

1
2
3 386 strategy) or by failure of the implementation process, making it difficult to compare the current
4
5 387 study to others. It is important to evaluate the implementation processes in order to truly
6
7
8 388 understand the effectiveness of multifaceted strategies.
9

10
11 389 Another interesting thing to note is the fact that the costs for secondary care and alternative care
12
13 390 are higher in the intervention group than in the control group. This is in contrast with a very
14
15 391 similar recent implementation study for the management of LBP. In that study, patients in the
16
17 392 intervention group had higher LBP-related costs for primary care, but lower LBP-related costs
18
19 393 for secondary care.^[46] Other studies within and outside the field of LBP however have shown
20
21 394 similar results to the current study, where patients and participants in intervention groups show
22
23 395 higher total medical care costs due to secondary care and/or alternative care.^[47-51] The literature
24
25 396 does not provide explanations for this fact. One explanation could lie, again, in the low
26
27 397 compliance rate of patients in this study.^[20] On the other hand, the use of alternative care could
28
29 398 be seen as self-management, because patients decide what they want, when they want it, and
30
31 399 how much they are willing to pay for it. It could very well be that patients try self-management
32
33 400 through alternative care for a while, and then get referred to secondary care when and because
34
35 401 self-management (through alternative care) did not work for them. It would be interesting to
36
37 402 explore the reasons for the higher costs for secondary care further.
38
39
40
41
42
43

44 403 While the strategy evaluated in this study did not yield effective results, it might still be
45
46 404 worthwhile considering the possibilities of eHealth interventions from the perspective of
47
48 405 outcomes that were not measured in this study but might have improved, for example actual
49
50 406 self-management. A systematic review of randomised controlled trials that have assessed self-
51
52 407 management education programmes for osteoarthritis found a mismatch between the aims of
53
54 408 such programmes (education and advice about how to self-manage their condition despite their
55
56 409 pain and fears) and how the success of the programmes were assessed.^[52] Many studies have
57
58 410 measured health-related outcomes such as pain and function but have not specifically
59
60

1
2
3 411 determined whether the programmes have improved participants' ability to self-manage.
4
5 412 Outcomes such as knowledge about the condition and self-management skills may give more
6
7 413 insight into the value of self-management education programmes and should be considered
8
9 414 essential to measure in future studies evaluating these types of programmes.^[52] Looking at the
10
11 415 cost savings on absenteeism, presenteeism and unpaid productivity losses in the intervention
12
13 416 group compared to the control group, future studies could also benefit from evaluating the
14
15 417 effects and cost-effectiveness of eHealth strategies from employer's perspective.
16
17
18
19

20 418 **Study limitations**

21
22
23 419 The findings of this study must be interpreted with caution. In this study, the loss-to-follow-up
24
25 420 rate was higher for the intervention group (40%) compared to the control group (23%). A
26
27 421 possible explanation could be that the strategy provided too much information and participants
28
29 422 were contacted too often, making them less willing to comply with completion of the
30
31 423 questionnaires over time. A comparison between patients that completed the study and patients
32
33 424 that were lost to follow-up showed that, in both the intervention and the control group, patients
34
35 425 that completed the study were more likely to have a high educational background. Additionally,
36
37 426 in the intervention group, patients that completed the study were more likely to not be employed
38
39 427 (i.e. involved in paid work) than patients that were lost to follow-up. The high percentage of
40
41 428 loss to follow-up may have resulted in a loss of power and in attrition bias. Additionally, it
42
43 429 underlines the need to take educational backgrounds and daily activities of participants into
44
45 430 account in designing studies and interventions. Furthermore, the majority of participants did
46
47 431 not need or use the intervention, and had minimal disability and impaired quality of life at
48
49 432 baseline impacting upon our ability to test the value of our intervention. Unfortunately, the
50
51 433 eHealth strategy is no longer accessible, which makes repeating of this study difficult. As the
52
53 434 strategy was financed through the funding for the trial, no financial resources were available to
54
55 435 keep the eHealth strategy functioning after the trial ended and funding stopped. Materials and
56
57
58
59
60

1
2
3 436 screenshots are still available for future use. Lastly, as for the lack of significant cost differences
4
5 437 in light of the cost-utility analysis, it is known that cost data are highly skewed and therefore
6
7 438 require large sample sizes to detect statistically significant differences.^[53] In this study, the
8
9 439 sample size calculation was based on back pain beliefs, which may have underpowered it to
10
11 440 detect significant cost differences.
12
13
14

15 441 **Conclusion**

16
17
18 442 Based on this study, a multifaceted eHealth strategy for patients who had presented to primary
19
20 443 care (i.e. general practice and physiotherapy) with LBP was not effective in improving back
21
22 444 pain beliefs, disability, or absenteeism. However, the cost-utility analysis based on QALYs
23
24 445 showed promising results. The multifaceted eHealth strategy should be studied in a different
25
26 446 population, i.e. a more mixed group of participants in terms of background (e.g. education,
27
28 447 nationality), and participants with LBP and poorer health states at start of the intervention.
29
30
31
32

33 448

34 35 36 449 **FIGURE LEGENDS**

37
38
39 450 Figure 1. Design of the stepped-wedge cluster randomised controlled trial

40
41
42 451 Figure 2. Flow-chart of patient inclusion

43
44
45 452 Figure 3. Cost-effectiveness plane for QALYs

46
47
48 453 Figure 4. CEAC for QALYs

49
50
51
52 454

53
54
55 455
56
57
58
59
60

456 **REFERENCES**

- 457 1. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back
458 pain. *Arthritis Rheum* 2012;64(6):2028-37.
- 459 2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional,
460 and national incidence, prevalence, and years lived with disability for 328 diseases and
461 injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of
462 Disease Study 2016. *Lancet* 2017; 390:1211–59.
- 463 3. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates from the
464 Global Burden of Disease 2010 Study. *Ann Rheum Dis* 2014;73:968-974.
- 465 4. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care
466 expenditures among individuals with back pain in the United States. *Spine* 2004;29(1):79–
467 86.
- 468 5. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000;84:95-
469 103.2.
- 470 6. Walker BF, Muller R, Grant WD. Low Back Pain in Australian Adults: The Economic
471 Burden. *Asia Pac J Public Health* 2003;15(2):79-87.
- 472 7. RIVM Kosten van ziekten database 2013. Kosten van zorg voor nek- en rugklachten. (In
473 English: Cost of care for neck- and back pain). Accessed 26-07-2017 through
474 [https://www.volksgezondheidenzorg.info/onderwerp/nek-en-
475 rugklachten/kosten/kosten#node-kosten-van-zorg-voor-nek-en-rugklachten](https://www.volksgezondheidenzorg.info/onderwerp/nek-en-rugklachten/kosten/kosten#node-kosten-van-zorg-voor-nek-en-rugklachten).
- 476 8. Lambeek LC, Van Tulder MW, Swinkels CS, Koppes LLJ, Anema JR, Van Mechelen W.
477 The Trend in Total Cost of Back Pain in the Netherlands in the Period 2002 to 2007. *Spine*
478 2011;36(13):1050-58.

- 1
2
3 479 9. Ki Ng S, Cicuttini FM, Wang Y, Wluka AE, Fitzgibbon B, Urquhart DM. Negative beliefs
4
5 480 about low back pain are associated with persistent high intensity low back pain. *Psychology,*
6
7 481 *Health & Medicine* 2017; 22(7):790-799.
- 8
9
10 482 10. Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear
11
12 483 avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back
13
14 484 pain: a systematic review. *The Spine Journal* 2014;14(5):816-836.e4.
- 15
16
17 485 11. Main CJ, Foster N, Buchbinder R. How important are back pain beliefs and expectations
18
19 486 for satisfactory recovery from back pain? *Best Practice & Research Clinical Rheumatology*
20
21 487 2010; 24(2):205-2017.
- 22
23
24 488 12. Ferreira ML, Machado G, Latimer J, Maher C, Ferreira PH, Smeets RJ. Factors defining
25
26 489 care-seeking in low back pain—a meta-analysis of population based surveys. *Eur J Pain*
27
28 490 2010;14(7):747.e1-7.
- 29
30
31 491 13. Wong JJ, Côté P, Sutton DA, et al. Clinical practice guidelines for the noninvasive
32
33 492 management of low back pain: A systematic review by the Ontario Protocol for Traffic
34
35 493 Injury Management (OPTIMA) Collaboration. *Eur J Pain* 2016;21:201-216.
- 36
37
38 494 14. Huber M, Van Vliet M, Giezenberg M, Knottneurs JA. Towards a conceptual framework
39
40 495 relating to ‘Health as the ability to adapt and to self-manage’, Operationalisering
41
42 496 gezondheidsconcept. Driebergen: Louis Bolk Instituut; 2013.
- 43
44
45 497 15. Du S, Hu L, Dong J, et al. Self-management program for chronic low back pain: A
46
47 498 systematic review and meta-analysis. *Patient Education and Counseling* 2017;100(1):37-
48
49 499 49.
- 50
51
52 500 16. Elbert NJ, Van Os-Medendorp H, Van Renselaar W, et al. Effectiveness and cost-
53
54 501 effectiveness of eHealth interventions in somatic diseases: a systematic review of
55
56 502 systematic reviews and meta-analyses. *J Med Internet Res* 2014; 16(4):e110.

- 1
2
3 503 17. McLean S, Chandler D, Nurmatov U, et al. Telehealthcare for asthma. Cochrane Database
4
5 504 Syst Rev 2010(10):CD007717.
6
7
8 505 18. Suman A, Schaafsma FG, Elders PJ, van Tulder MW, Anema JR. Cost-effectiveness of a
9
10 506 multifaceted implementation strategy for the Dutch multidisciplinary guideline for
11
12 507 nonspecific low back pain: design of a stepped-wedge cluster randomised controlled trial.
13
14 508 BMC Public Health 2015;15:522; doi: 10.1186/s12889-015-1876-1.
15
16
17 509 19. Buchbinder R, Jolley D, Wyatt M: 2001 Volvo Award Winner in Clinical Studies: Effects
18
19 510 of a Media Campaign on Back Pain Beliefs and Its Potential Influence on Management of
20
21 511 Low Back Pain in General Practice. Spine. 2001;26(23):2535-2542.
22
23
24 512 20. Suman A, Schaafsma FG, Bamarni J, van Tulder MW, Anema JR. A multimedia campaign
25
26 513 to improve back beliefs in patients with non-specific low back pain: a process evaluation.
27
28 514 BMC Musculoskelet Disord 2017; 18;18(1):200.
29
30
31 515 21. Suman A, Schaafsma FG, Buchbinder R, van Tulder MW, Anema JR. Implementation of a
32
33 516 Multidisciplinary Guideline for Low Back Pain: Process-Evaluation Among Health Care
34
35 517 Professionals. J Occup Rehabil 2017; 27(3):422-433.
36
37
38 518 22. Suman A, Schaafsma FG, Van de Ven PM, et al. Effectiveness of a multifaceted
39
40 519 implementation strategy compared to usual care on low back pain guideline adherence
41
42 520 among general practitioners. BMC Health Serv Res 2019; 18(1):358.
43
44 521
45
46
47 522 23. Symonds TL, Burton AK, Tillotson KM, Main CJ. Do attitudes and beliefs influence work
48
49 523 loss due to low back trouble? Occup Med 1996;46(1):25-32.
50
51
52 524 24. Bostick GP, Schopflocher D, Gross DP. Validity evidence for the back beliefs questionnaire
53
54 525 in the general population. Eur J Pain 2013;17(7):10745-81;doi:10.1002/j.1532-
55
56 526 2149.2012.00275.x.
57
58
59
60

- 1
2
3 527 25. Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and the Oswestry
4
5 528 Disability Questionnaire. *SPINE* 2000;25(24):3115-3124.
6
7
8 529 26. Brooks, R. EuroQol: The current state of play. *Health Policy* 1996;37:53–72.
9
10 530 27. Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for
11
12 531 economic evaluation studies. *Expert Review of Pharmacoeconomics & Outcomes Research*
13
14 532 2005;5(1).
15
16
17 533 28. Bouwmans C, De Jong K, Timman R, et al. Feasibility, reliability and validity of a
18
19 534 questionnaire on healthcare consumption and productivity loss in patients with a psychiatric
20
21 535 disorder (TiC-P). *BMC Health Services Research*. 2013;13:217;doi:10.1186/1472-6963-
22
23 536 13-217.
24
25
26 537 29. Lamers LM, McDonnell J, Krabbe PFM, van Busschbach JJ. Kwaliteit van leven in
27
28 538 economische evaluaties: het Nederlands EQ-5D tarief. *Ned Tijdschr Geneeskd*
29
30 539 2005;149:1574-78.
31
32
33 540 30. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de
34
35 541 gezondheidszorg. Diemen: Zorginstituut; 2016
36
37
38 542 31. Z-Index. G-standard. The Hague: Z-Index BV; 2009.
39
40 543 32. Groenwold R, Donders AR, Roes K, Harrell F, Moons K. Dealing with missing outcome
41
42 544 data in randomized trials and observational studies. *Am J Epidemiol* 2012;175:210-7.
43
44
45 545 33. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in
46
47 546 epidemiological and clinical research: potentiation and pitfalls. *BMJ* 2009;338:b2393.
48
49 547 34. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and
50
51 548 guidance for practice. *Stat Med* 2011;30:377-99.
52
53
54 549 35. Rubin D. Multiple imputation for nonresponse in surveys. Hoboken, New Jersey: John
55
56 550 Wiley & Sons; 2004.
57
58
59
60

- 1
2
3 551 36. Twisk JWR. Applied multilevel analysis: a practical guide for medical researchers.
4
5 552 Cambridge: Cambridge University Press; 2006.
6
7
8 553
9
10 554 37. Willian A, Briggs A, Hock J. Regression methods for covariate adjustment and subgroup
11
12 555 analysis for non-censored cost-effectiveness data. Health Economics 2004;13:461-75.
13
14 556 38. Black W. The CE plane: a graphic representation of cost-effectiveness. Med Dec Making
15
16 557 1990;10:212-14.
17
18
19 558 39. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies
20
21 559 and frequently asked questions. Health Economics 2004;13:405-15.
22
23
24 560 40. Buchbinder R, Jolley D, Wyatt M. Population based intervention to change back pain beliefs
25
26 561 and disability: three part evaluation. BMJ 2001;322(7301):1516-1520.
27
28
29 562 41. Teixeira LF, Pereira LS, Silva SL, Dias JM, Dias RC. Factors associated with attitudes and
30
31 563 beliefs of elders with acute low back pain: data from the study Back Complaints in the
32
33 564 Elders (BACE). Braz J Phys Ther 2016;20(6):553-560;doi:10.1590/bjpt-rbf.2014.0188.
34
35
36 565 42. National Institute for HealthCare Excellence (NICE). 2016. Low back pain and sciatica in
37
38 566 over 16s: assessment and management. NICE guideline [NG59]. Accessed 19-01-2018
39
40 567 through <https://www.nice.org.uk/guidance/ng59>.
41
42
43 568 43. Oliveira VC, Ferreira PH, Maher CG, Pinto RZ, Refshauge KM, Ferreira ML. Effectiveness
44
45 569 of self-management of low back pain: systematic review with meta-analysis. Arthritis Care
46
47 570 & Research 2012;64(11):1739-1748.
48
49
50 571 44. Nicholl BI, Sandal LF, Stochkendahl MJ, et al. Digital support interventions for the self-
51
52 572 management of low back pain: a systematic review. Journal of Medical Internet Research
53
54 573 2017;19(5):e179.
55
56
57 574 45. Suman A, Dikkers MF, Schaafsma FG, Van Tulder MW, Anema JR.. Effectiveness of
58
59 575 multifaceted implementation strategies for the implementation of back and neck pain
60

- 1
2
3 576 guidelines in health care: a systematic review. *Implementation Science*
4
5 577 2016;11:126;doi:10.1186/s13012-016-0482-7.
6
7
8 578 46. Jensen CE, Riis A, Petersen KD, Jensen MB, Pedersen KM. Economic evaluation of an
9
10 579 implementation strategy for the management of low back pain in general practice. *Pain*
11
12 580 2017;158(5):891-899.
13
14
15 581 47. Lammerts L, Van Dongen JM, Schaafsma FG, Van Mechelen W, Anema JR. A
16
17 582 participatory supportive return to work program for workers without an employment
18
19 583 contract, sick-listed due to a common mental disorder: an economic evaluation alongside a
20
21 584 randomized controlled trial. *BMC Public Health* 2017;17:162;doi:10.1186/s12889-017-
22
23 585 4079-0.
24
25
26 586 48. Noben C, Vilsteren MV, Boot C, et al. Economic evaluation of an intervention program
27
28 587 with the aim to improve at-work productivity for workers with rheumatoid arthritis. *J Occup*
29
30 588 *Health* 2017;59(3):267-279.
31
32
33 589 49. Van der Meer EW, Van Dongen JM, Boot CR, Van der Gulden JW, Bosmans JE, Anema
34
35 590 JR. Economic evaluation of a multifaceted implementation strategy for the prevention of
36
37 591 hand eczema among healthcare workers in comparison with a control group: the Hands4U
38
39 592 study. *Acta Derm Venereol* 2016;96(4):499-504.
40
41
42 593 50. Van Oostrom SH, Heymans MW, De Vet HCW, Van Tulder MW, Van Mechelen M,
43
44 594 Anema JR. Economic evaluation of a workplace intervention for sick-listed employees with
45
46 595 distress. *Occupational and Environmental Medicine* 2010;67:603-610.
47
48
49 596 51. Van der Roer N, Van Tulder M, Van Mechelen W, De Vet H. Economic evaluation of an
50
51 597 intensive group training protocol compared with usual care physiotherapy in patients with
52
53 598 chronic low back pain. *Spine* 2008;33(4):445-51.
54
55
56
57
58
59
60

- 1
2
3 599 52. Kroon FP, Van der Burg LR, Buchbinder R, Osborne RH, Johnston RV, Pitt V. Self-
4
5 600 management education programmes for osteoarthritis. Cochrane Database Syst Rev
6
7 601 2014;15(1): CD008963.
8
9
10 602 53. Briggs A. Economic evaluation and clinical trials: size matters. BMJ 2000;321:1362–1363.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

	T0 (Baseline)	T1 (3 months)	T2 (6 months)	T3 (9 months)	T4 (12 months)
Cluster 1	Control	Intervention	Intervention	Intervention	Intervention
Cluster 2	Control	Control	Intervention	Intervention	Intervention
Cluster 3	Control	Control	Control	Intervention	Intervention
Cluster 4	Control	Control	Control	Control	Intervention

Figure 1. Design of the stepped-wedge cluster randomised controlled trial





Figure 2. Flow-chart of patient inclusion



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

• Bootstrapped estimates • Point estimate




Table 1: CONSORT 2010 checklist of information to include when reporting a cluster randomised trial

Section/Topic	Item No	Standard Checklist item	Extension for cluster designs	Page No *
Title and abstract				
	1a	Identification as a randomised trial in the title	Identification as a cluster randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) ^{1,2}	See table 2	3-4
Introduction				
Background and objectives	2a	Scientific background and explanation of rationale	Rationale for using a cluster design	6
	2b	Specific objectives or hypotheses	Whether objectives pertain to the cluster level, the individual participant level or both	7
Methods				
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Definition of cluster and description of how the design features apply to the clusters	8
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons		N/A
Participants	4a	Eligibility criteria for participants	Eligibility criteria for clusters	8-9
	4b	Settings and locations where the data were collected		8
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Whether interventions pertain to the cluster level, the individual participant level or both	9-10
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and	Whether outcome measures pertain to the cluster level, the individual participant level or both	10-13

		when they were assessed		
	6b	Any changes to trial outcomes after the trial commenced, with reasons		11
Sample size	7a	How sample size was determined	Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or <i>k</i>), and an indication of its uncertainty	10-11
	7b	When applicable, explanation of any interim analyses and stopping guidelines		N/A
Randomisation:				
Sequence generation	8a	Method used to generate the random allocation sequence		9
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Details of stratification or matching if used	9
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both	9
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Replace by 10a, 10b and 10c	9
	10a		Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions	9
	10b		Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete	9

		enumeration, random sampling)		
	10c		From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation	N/A
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how		9
	11b	If relevant, description of the similarity of interventions		N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	How clustering was taken into account	13-14
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		13-14
Results				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome	15
	13b	For each group, losses and exclusions after randomisation, together with reasons	For each group, losses and exclusions for both clusters and individual cluster members	15
Recruitment	14a	Dates defining the periods of recruitment and follow-up		8
	14b	Why the trial ended or was stopped		N/A
Baseline data	15	A table showing baseline demographic and clinical	Baseline characteristics for the individual and cluster levels as	16-17

		characteristics for each group	applicable for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	For each group, number of clusters included in each analysis	15-19
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for each primary outcome	15-19
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		15-19
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		15-21
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms ³)		N/A
Discussion				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		22-26
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Generalisability to clusters and/or individual participants (as relevant)	22-26
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		22-26
Other information				
Registration	23	Registration number and		4

		name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	4
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	4

* Note: page numbers optional depending on journal requirements

For peer review only

Table 2: Extension of CONSORT for abstracts^{1,2} to reports of cluster randomised trials

Item	Standard Checklist item	Extension for cluster trials
Title	Identification of study as randomised	Identification of study as cluster randomised
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)	
Methods		
Participants	Eligibility criteria for participants and the settings where the data were collected	Eligibility criteria for clusters
Interventions	Interventions intended for each group	
Objective	Specific objective or hypothesis	Whether objective or hypothesis pertains to the cluster level, the individual participant level or both
Outcome	Clearly defined primary outcome for this report	Whether the primary outcome pertains to the cluster level, the individual participant level or both
Randomization	How participants were allocated to interventions	How clusters were allocated to interventions
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	
Results		
Numbers randomized	Number of participants randomized to each group	Number of clusters randomized to each group
Recruitment	Trial status ¹	
Numbers analysed	Number of participants analysed in each group	Number of clusters analysed in each group
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision	Results at the cluster or individual participant level as applicable for each primary outcome
Harms	Important adverse events or side effects	
Conclusions	General interpretation of the results	
Trial registration	Registration number and name of trial register	
Funding	Source of funding	

¹ Relevant to Conference Abstracts

REFERENCES

- 1 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 2008, 371:281-283
- 2 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 5(1): e20
- 3 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004; 141(10):781-788.

For peer review only

CHEERS checklist—Items to include when reporting economic evaluations of health interventions

Section/item	Item No	Recommendation	Reported on page No/ line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	3-4
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study.	6-7
		Present the study question and its relevance for health policy or practice decisions.	6-7
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	8-9
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	8
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	8-14
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	9-10
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	8-14
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	N/A
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	10-14
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	8-14
	11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	N/A
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	N/A
Estimating resources and costs	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	12-14
	13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate	N/A

Section/item	Item No	Recommendation	Reported on page No/ line No
		resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	10-14
Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	N/A
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	N/A
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	10-14
Results			
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	19-21
Incremental costs and outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	19-21
Characterising uncertainty	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).	19-21
	20b	<i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	N/A
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	19-21
Discussion			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	22-26
Other			
Source of funding	23	Describe how the study was funded and the role of	4

Section/item	Item No	Recommendation	Reported on page No/ line No
		the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	4-5
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist			

For peer review only

Intervention component	Cost category	Units	Unit prices	Total costs (Euros 2016)	Costs per patient (Euros 2016)
<i>Professional intervention</i>					
<i>Development costs</i>					
CME training material by Junior reseacher **	Labor costs	6 months	2.618,- per month	15.708,00	0,01
<i>Training costs</i>					
Accreditation by professional associations *	Capital costs	1	484,-	484,00	1,51
Training material *	Capital costs	96	9,03	866,26	2,71
Printing training material *	Capital costs	96	4,46	428,20	1,34
Training locations *	Capital costs	7	51,86	363,00	1,14
Catering during training *	Capital costs	7	164,91	1.154,35	3,61
Participation costs GPs *	Labor costs	31 GPs/3 hours per GP	81,75/hour	7.602,75	23,76
Participating costs OPs *	Labor costs	23 OPs/3 hours per OP	81,75/hour	5.640,75	17,63

Participating costs PTs *	Labor costs	42 PTs/3 hours per PT	22,22/hour	2.799,72	8,75
Participating costs Junior researcher *	Labor costs	18 hours	33,63/hour	605,34	1,89
Participating costs Senior researcher *	Labor costs	12 hours	68,49/hour	821,88	2,57
Participating costs Principal Investigator *	Labor costs	12 hours	126,26/hour	1.515,12	4,74
<i>Patient intervention</i>					
<i>Development costs</i>					
Intervention material by Junior researcher **	Labor costs	6 months	2.618,- per month	15.708,00	0,01
Videomessages by professionals actors **	Labor costs	12 actors	139,67	1.675,98	0,01
Traveling expenses professional actors **	Capital costs	12 actors	7,56	90,62	0,01
Development of videomessages **	Capital costs	12 videos	610,78	7.329,41	0,01
Development of voice-over videomessages **	Capital costs	12 videos	58,38	700,60	0,01
Development of translations **	Capital costs	1	430,-	430,00	0,01
<i>Intervention costs</i>					

Website hosting **	Capital costs	3 years	193,92	581,75	0,01
Total intervention costs			Total	64.505,73	69,73
* Costs per patient					
** Costs per patient for all patients in the Netherlands (n=2 million)					

Unit	Price weight (€, 2016)
Intervention costs (per patient)	69,73
<i>Medical costs</i>	
<i>General practitioner</i>	
Office consultation	33,31
Telephone consultation	17,16
House call	50,46
Occupational physician	25,84
Physiotherapist	33,31
Occupational therapist	33,31
Dietician	29,95
Homeopath	67,08
Psychologist	93,17
Psychotherapist	84,74
Psychiatrist	94,87
Other medical specialists	91,84
Emergency room	261,40
Outpatient clinic visit	91,84
Hospitalization (per day)	480,41
<i>Medication</i>	
Medication	Variable
<i>Alternative care</i>	
Alternative care	Variable
<i>Absenteeism costs</i>	
Sick leave days	Variable, depended on gender and age
<i>Presenteeism costs</i>	
Presenteeism score	Variable, depended on gender and age